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STELLING EN behorenden bij het proefschrift getiteld 
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I. In clinical practice, most often the contralateral, non-affected side of a patient is used as reference for the identification of sensory signs at the affected side. In unilateral neuropathic pain bilateral somatosensory changes i.e. changes at the affected as well as the contralateral side occur frequently. To avoid potential misjudgement of the quality of sensory abnormali­ties we suggested that QST reference values obtained from healthy controls should be used. 
2. Despite similar numbers of sensory abnormalities for the different grades of neuropathic pain, aspects of the pattern of sensory signs were different between 'definite' and 'probable' neuropathic pain and 'unlikely' neuropathic pain. The identification of differences in patterns of sensory abnormality in neuropathic pain patients could lead to a mechanistic understanding of somatosensory abnormalities in neuropathic pain. 
3. A single QST parameter, i.e. mechanical pain sensitivity (MPS), can be u�ed to identify distinct subgroups of neuropathic pain patients. a. QST phenotypic characterization e.g. MPS response pattern, as a tool for patient selection for enrolment into clinical trials could be used to decrease variance and increase the power to detect meaningful drug effects. 
b. Pharmacological intervention studies of patients with different response pattern to MPS could also help to determine a mechanism-based therapy for neuropathic pain. 
4. Sensitisation may play a role in the explanation of pain during and after sports activity in patients with patella tendinopathy. Results of this QST study indicate that treatment and medical management of tendinopathies could be adapted accordingly. 
5. Improved knowledge of the subjective nature of pain and related sensory processes e.g. somatosensory functioning could help to optimize the choice of pain patient study population and appropriate measurements for proof-of concept trails with putative pain therapies. 
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1. General introduction 
Aristotle (384 to 322 BC) (Fig.1-1), the great Greek 
philosopher, was the first to describe "sense". He described 
five senses: sight, hearing, taste, smell, and touch. For 
Aristotle, the brain had no function in sensory processing. 
The sensorium commune, or center of sensory perception, 
was located in the heart, which he considered the center 
of all the fundamental life functions and the location of 
the soul. He contemplated the function of the brain to be 
limited to the production of cool secretions that cooled the 
hot air and blood arising from the heart. For him, an excess 
of vital heat in combination with an increased sensitivity Figure 1-1: Picture of 
to sensations, in particular touch, was responsible for the Aristotle 
"emotion" pain (Bonica 1991). From: biography4u.com 
Today we still believe there are five senses including touch. Arrays ofreceptors such as 
Pacinian and Meissner corpuscles, Merkel's disks and Ruffini endings sense different 
aspects of touch throughout our bodies. They are tuned to different aspects of the 
somatosensory world - touch, temperature and body position - with yet others for the 
sensations of pain. Although often classed with touch, pain is actually a phenomenon 
serving different functions and involves a different anatomical organisation.We 
recognise peripheral nerves, the spinal cord and the brain as major structures involved 
in the perception and interpretation of painful sensory information. The interplay of 
sensory information within these structures is not only relevant for the perception of 
pain per se but it also enables pain to serve a biologically important protective function. 
In this context, the sensation of pain is a normal response to injury or disease and 
induces withdraw from potentially damaging situations and protects a damaged body 
part while it heals. 
In the last few decades basic research brought detailed understanding of concepts and 
theories regarding pain mechanisms. In 1965, Pat Wall and Ron Melzack published 
their paper in Science, entitled a 'New Theory of Pain' (Melzack & Wall 1965). The gate 
control theory stated that the transmission of pain from the peripheral nerve through 
the spinal cord was subject to modulation by both intrinsic neurons and controls from 
the brain. This theory explains how the central nervous system deals with sensory 
inputs but does not emphasise peripheral processes. In the peripheral nervous system 
there are three main types of sensory fibres involved in the sensory experience, A�­
fibres, A8-fibres, and C-fibres (Fig. 1-2). A�-fibres are large in diameter and highly 
myelinated, allowing a fast conduction of action potentials. These fibres have low 
activation thresholds and normally respond to light touch. A8-fibres are smaller in 
diameter and thinly myelinated, and therefore slower-conducting than A�-fibres. A8-
fibres have higher activation thresholds and respond to both thermal and mechanical 
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stimuli. C-fibres are unmyelinated and the smallest and the slowest conducting type of 
primary afferents. They have the highest thresholds for activation and therefore detect 
selectively nociceptive or 'painful' stimuli. Collectively, both Ab- and C-fibres can be 
termed as nociceptors or 'pain fibres', responding to noxious stimuli which may be 
mechanical, thermal, or chemical (D'Mello & Dickenson 2008). However, this might 
be a simplistic presumption since other authors now consider some A�-afferents also as 
nociceptors (Djouhri & Lawson 2004). These fibres are affected in clinical pains which 
may arise from different sources, for instance damage to tissue due to inflammation or 
damage to nerves in case of so-called neuropathic pain (Baron 2000; 2006; Basbaum 
et al 2009; Melzack et al 2001 ). Both may cause subsequent profound changes in the 
spinal cord  and the brain. 
It is believed that all persistent forms of pain induce plasticity including altered 
mechanisms in peripheral and central signalling, suggesting that the mechanisms 
involved in pain are likely to be multiple and located at a number of sites (Dickenson 
1995; Dickenson et al 2002; Schaible 2007; Treede et al 1992). In 1970, David Hubel and 
Torsten Wiesel published intriguing results of plastic changes in the brain in their work 
with kittens ( Hubel & Wiesel 1970). In their experiments, they shut one eye by sewing 
the eyelids together and electrophysiologically recorded cortical brain maps. They saw 
that the portion of the kitten's brain associated with the shut eye was not inactive, as 
expected.  Instead, it processed visual information from the open eye. This property 
of the ner vous system to adapt morphologically and functiona11y to external stimuli is 
known as neuroplasticity. 
Altered mechanisms in the peripheral and central signalling in chronic pain can lead to 
hypersensitivity to peripheral stimuli. Two typesofhypersensitivitycan be distinguished.  
First, allodynia is defined as pain in response to a non-nociceptive stimulus. In cases 
of mechanical allodynia, even gentle mechanical stimuli such as a slight touch can 
evoke severe pain. Second, hyperalgesia is defined as increased pain sensitivity to a 
nociceptive stimulus. Here, patients experience a painful stimulus such as a prick with 
greater intensity. Both, peripheral and central sensitisations are known to be involved in 
the generation of hypersensitivity. Peripheral sensitisation is a reduction in threshold and 
an increase in responsiveness of the peripheral ends of nociceptors. W hereas, �al 
�sitisafion is an increase in the excitability of neurons within the central nervous 
system, so that normal inputs produce abnormal responses. The increased excitability 
is typically triggered by a burst of activity in nociceptors, which alter the strength 
of synaptic connections between the nociceptor and the neurons of the spinal cord 
(so-called activity-dependent synaptic plasticity) ( Hunt & Mantyh 2001; Woolf 2010; 
Woolf & Mannion 1999). As a result, an input that would normally evoke an innocuous 
sensation may now produce pain (Scholz & Woo1f2002; Woolf & Salter 2000). Altered 
peripheral and central signalling could be regarded as the structural correlate leading to 
16 
1. General introduction ongoing pain, hyperalgesia and / or allodynia which are frequently reported by patients with neuropathic pain. Primary afferent fibres (A�-, A�-, and C-fibres) transmit impulses fromthe periphery, through the dorsal root ganglion (DRG) and into the ...Q.,Q_rsal horn of the spinal cord. Nociceptive specific (NS) cells are mainly found in the superficial dorsal hor,11 (laminae 
I-II), whereas most wide dynamic ranges (WDRs) are located deeper (lamina V). Projection neurones from lamina I iunervaj:e arw such as the parabrachial area (PB) and periaqueductal gre� and such pathways are affected by limbic areas. From here descending pathways (yellow arrows) from brainstem nuclei such as the rostral ventromedial medulla (RVM) are activated and modulate spinal processing. Lamina V neurones mainly project to the thalamus (spinothalamic tract), and from here the various cortical regions forming the 'pain matrix' (primary and secondary somatosensory, insular, anterior cingulate, and prefrontal cortices) are activated. Figure 1-2: Pain pathways from periphery to brain From: D'Mello R., Dickenson A.H., Br. J. Anaesth. 2008;101:8-16 (with permission). 
1.1. Neuropathic pain The International Association for the Study of Pain (IASP) defined pain as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage". Most pain resolves quickly but sometimes pain becomes chronic despite removal of the stimulus and apparent healing of the body. Chronic pain is defined as pain lasting more than three months (Woolf & Mannion 1999). A specific subclass of chronic pain is neuropathic pain. The IASP defined neuropathic pain as a direct consequence of a lesion or disease affecting the somatosensory system (Treede et al 2008). The prevalence of neuropathic pain is estimated to be as much as 7-8% of the general population in Europe (Bouhassira et al 2008; Torrance et al 2006). Clinical entities of neuropathic pain include diabetic polyneuropathies, postherpetic neuralgia, trigeminal neuralgia, central post stroke pain and spinal cord injury pain. But also traumatic / postsurgical neuropathies and painful radiculopathies represent common conditions (Torrance et al 2006). 
17 
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1 .  Gene ·al introduction Patients report that their neuropathic pain symptoms often have a burning, lancinating, or shooting quality with unusual tingling, crawling, or electrical sensations (Bennett et al 2007), which can be persistent or paroxysmal pain that is independent of a stimulus (Woolf & Mannion 1999). Patients with neuropathic pain may also experience evoked pain (i.e., stimulus-induced pain and hypersensitivity), mostly reported as mechanical and/or thermal hypersensitivity. Table 1-1 shows a summary of terms to describe symptoms and sensory signs commonly seen in neuropathic pain patients. Neuropathic pain can be very disabling, severe and intractable for patients. The understanding of the underlying neurobiological processes in neuropathic pain is still evolving (Haanpaa et al 2009). The Joint Commission on Accreditation of Healthcare Organizations, USA, acknowledged the lack of understanding in the field of pain and declared the ten-years beginning 2001 as the "Decade of Pain Control and Research". Since the beginning of the new millennium pain is also regarded as the fifth vital sign. 
Table 1-1: Common symptoms and signs in neuropathic pain TERMS DEFINITION 
Symptoms Paresthesias Non-painful positive sensations ("ant-crawling", "tingling") Burning pain Frequent quality of spontaneous pain sensations Shooting pain Spontaneous or evoked intense pain sensations of several seconds duration 
Signs Hypesthesia Impaired sensitivity to a stimulus Tactile hypesthesia Impaired sensitivity to tactile stimuli Cold hypesthesia Impaired sensitivity to cold Hypoalgesia Impaired sensitivity to a normally painful stimulus Hyperalgesia Increased pain sensitivity (may include a decrease in threshold and an increase in supra threshold response) Punctate hyperalgesia Hyperalgesia to punctuate stimuli such as pinprick Static hyperalgesia Hyperalgesia to blunt pressure Heat hyperalgesia Hyperalgesia to heat stimuli Cold hyperalgesia Hyperalgesia to cold stimuli Allodynia Pain due to a non-nociceptive tactile stimulus Adapted from Haanpaa, M.L. et al., 2009; Am J Med , 2009; 122:S13-21 
L Cc, en ! intr ld t c 
1.1.1. Diagnosis of neuropathic pain 
Neuropathic pain is characterised by spontaneous and evoked pain (Fig. 1-3), by other 
positive symptoms such as paresthesias and by negative signs reflecting the neural 
damage ( Table 1-1). It is not possible to determine the aetiology of neuropathic pain 
from the clinical characteristics of the pain (Attal et al 2008). Therefore, the diagnosis 
neuropathic pain should be made on grounds of coherent patient history and medical 
examination. Investigations of spontaneous pain features include "Neuropathic 
Symptoms Tools" such as pain scales, inventories and questionnaires. Physical 
examinations such as bedside tests are aimed to qualify sensory abnormalities. 
Additional appropriate laboratory studies including blood and serologic tests, magnetic 
resonance imaging, and electrophysiological studies should be conducted. In some 
instances, nerve or skin biopsy is necessary to directly visualise nerve fibres. Detailed 
guidelines on neuropathic pain assessment have been described recently (Cruccu et al 
201 O; Haanpaa et al 2010). 
Neuropathic pain 
spontaneous pain evoked pain 
continuous intermittent allodynia hyperalgesia 
mechanical thermal 
static/dynamic cold/warm 
Figure 1 -3: Components of neuropathic pain; adapted from Woolf C.J., Mannion R.J.,Lancet 
1 999; 353: 1 959-1 964 
Neuropathic pain is not only very challenging to diagnose but also to manage due to 
the heterogeneity of its aetiologies, symptoms and underlying mechanisms (Beniczky 
et al 2005). 
1.1.2. Treatment of neuropathic pain 
Neuropathic pain is often difficult to treat, as many medications are ineffective and/or, if 
effective, lead to intolerable adverse effects. Drugs that are used to manage neuropathic 
pain include antidepressants, anti-convulsant drugs, opioids and topical treatments such 
as capsaicin and lidocaine. Simple analgesics such as non-steroidal anti-inflammatory 
1 9  
-, 
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drugs (NSAIDS) and paracetamol are considered not to be efficacious for this type of 
pain ( Dickenson 1995). Many patients require treatment with more than one drug or 
classes of drugs,  but the correct choice of drugs, and the optimal sequence for their use, 
is still not defined. Therefore, management of pain should be tailored to the individual 
patient on the basis of type of pain, the causative disease, and psychosocial aspects. 
A treatment cascade was implemented recently, incorporating an evidence-based 
symptomatic pharmacotherapy of neuropathic pain (Attal et al 2010; Dworkin et al 
2007b). 
During the last decades, basic pain research brought detailed understanding of concepts 
and theories regarding pain mechanisms such as the gate control theory (Melzack 
& Wall 1965) the concept of neuroplasticity (Melzack et al 2001; Woolf & Salter 
2000), and an understanding of the cellular and molecular mechanisms of peripheral 
and central sensitisation (Basbaum et al 2009; Hunt & Mantyh 2001; Ji et al 2003). 
These developments in the understanding of pain mechanisms have been translated 
into clinical practice, resulting in a multimodal approach to pain relief. However, in 
neuropathic pain patients a decrease of pain of more than 50% is only achieved in less 
than one-third of the patients studied (Argoff et al 2006; Farrar et al 2001; McQuay et 
al 1996; Sindrup & Jensen 1999; Ziegler 2008). The lack of efficacy could be based on 
the limiting side-effect profile or due to addictive properties of the drug, which might 
compromises the therapeutic dose window. On other hand,  such a lack in treatment 
efficacy might be based on the fact that neuropathic pain is still being classified based 
on its underlying aetiology (Hansson 2003; Jensen et al 2001; Woolf & Mannion 1999). 
There are, however, promising developments to address these short-comings. 
Recently, a more neurological approach to categorise neuropathic pain was suggested. 
In order to determine with a greater level of certainty whether a pain condition is 
neuropathic, a grading system of definite, probable, possible and unlikely neuropathic 
pain was proposed (Ireede et al 2008). Briefly, the grade 'unlikely' excludes patients 
lacking a history of a lesion o r  disease for a plausible neuroanatomical distribution 
of their pains. The grade 'possible' is regarded as a working hypothesis , which does 
not exclude, neither diagnoses neuropathic pain. Patients who fall into the category 
'possible' neuropathic pain can be transferred into the grades 'probable' and 'definite' 
if neurologic examination and / or a test e.g. MRI ,  biopsy or laboratory parameter 
confirm the diagnosis of the suspected lesion or disease, respectively. An advantage of 
this grading system is the precise identification of a lesion or disease and the ability to 
directly link these to somatosensory changes. 
A few years ago, a new hypothetical concept was proposed ,  in which pain is classified 
on the basis of underlying m.echanis.ms ( Dworkin et al 2003; Sindrup & Jensen 1999; 
Woolf et al 1998). Supportive to this concept are clinical experimental studies (Attal 
et al 2004; Baron et al 2009) indicating that a specific �mptom might be generated by 
several entirely different underlying patboph;ysiological mechanjsm_s. This implies that 
a specific s;ymptam profile rather than a single symptom might be required to predict 
the underlying mechanism (Baron 2006). It is obvious that new concepts such as a 
mechanism-based classification of neuropathic pain aiming for a better understanding 
and improved treatment for neuropathic pain should be further explored. Precise 
$)IDaloseA�ocy phenotyping of patients with neuropathic pain might enable the direct 
translation of these ideas into the clinic. In this context, a comprehensive understanding 
of the somatosensory representation of neuropathic pain is evolving and Qµantitative 
§_ensory �sting plays a major role on this stage. 
1.2. Quantitative Sensory Testing (QST) 
In 2006, Rolke and colleagues published sequential papers evaluating a quantitative 
sensory testing battery aimed to precisely characterize somatosensation in patients 
with neuropathic pain and healthy volunteers (for reference data) (Rolke et al 2006a; 
Rolke et al 2006b). Limited sensory testing such as bedside testing has been used by 
clinicians to identify and qualify neuropathic pain. In contrast, with the development of 
standardized Quantitative Sensory Testing (QST) protocols such as was provided by the 
German Research Network on Neuropathic Pain ( DFNS), a methodology is available 
to detect and quantify sensory loss and sensory gain in a standardized manner. This 
DFNS protocol uses 13 different mechanical and thermal stimuli (e.g. graded von Frey 
filaments, pin-prick devices, a pressure algometer, and quantitative thermo-testing). It 
takes about 30 minutes to test one location of the body in healthy volunteers, versus 
about 45 minutes in patients. 
This QST battery tests different sub-modalities of nerve fibres involved in the 
transduction of sensory information from the periphery to the spinal cord such as A�­
fibre, Ab-fibre and C-fibre (Table 1-2). When present, allodynia or hyperalgesia can 
be quantified by measuring intensity, threshold for elicitation and duration (Rolke et 
al 2006a; Rolke et al 2006b). It has been shown that QST is sensitive for quantifying 
sensory abnormalities on an individual patient level (Rolke et al 2006a). Subsequently, it 
may be presumed that QST applied in large patient samples might allow to discriminate 
distinct responders to the different stimuli on a group level. 
2 1  
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Table l-2: Simplified overview of nerve fibres sub-modalities tested by QST 
QST CPT HPT WDT WUR CPT TSL PHS M PT MPS M DT DMA VDT PPT 
parameter 
C-fibre X X X X X 
A8-fibre X X X X X X 
A�-fibre X X X 
Potential overlapping modalities for each nerve fibre type are not shown. QST parameters are: 
Cold Pain Threshold (CPT), Heat Pain Threshold (HPT), Warm Detection Threshold (WOT), Wind 
Up Ratio (WUR), Cold Detection Threshold (CDT), Thermal Sensory Limen (TSL), Paradoxical 
I lcat Sensation (PHS), Mechanical Pain Threshold (MPT), Mechanical Pain Sensitivity (MPS), 
Mechan ical Detection Threshold (MDT), Dynam ic Mechan ical Al lodynia (OMA), Vibration 
Disappearance Threshold (VDT) and Pressure Pain Threshold (PPT). A l l  nerve fibre functionality 
tests are appl ied to the skin with exception of PPT (deep tissue C-fibre/A8-fibre test). 
1.2.1. QST and homogenous groups of somatosensory abnormalities 
QST might offer a tool to identify homogenous groups of somatosensory abnormalities 
in patients with neuropathic pain for the evaluation of novel pain compounds. The 
approach currently used in clinical trials is the assessment of general pain relief values 
for specific aetiologies, which might partially explain the failure to obtain complete 
pain relief in neuropathic pain conditions (Baron 2006). This is in line with the Food 
and Drug Administration (FDA) that requests the inclusion of patient populations for 
clinical trial based on disease endpoints for the registration of pain medication. More 
pragmatic in the current environment is to use a disease endpoint recognised by the 
F DA but to reduce heterogeneity in the patient group in order to reduce variability in 
the trial and increase the power. A classification based on sensory abnormalities rather 
than based merely on aetiology could contribute to minimising pathophysiological 
heterogeneity within study groups (Attal et al 2008). Such an approach would recognise 
not only pain as an outcome measure but also addresses troublesome features such 
as hyperalgesia and allodynia frequently reported by patients with neuropathic pain. 
There is a need for a different method of evaluating pain medications to increase 
positive treatment responses e.g. increase assay sensitivity. QST-based identification 
of homogenous patient populations could help to clarify the relationships between 
the aetiology and somatosensory abnormalities in neuropathic pain patients. This is a 
particularly interesting approach when such groups of somatosensory-wise homogenous 
pain patients are investigated further with e.g. neuroimaging techniques to reveal 
potential group-specific changes in the brain. 
Human brain imaging studies show that structural changes and brain function changes 
in different neural regions including the thalamus , nucleus accumbens, basal ganglia , 
.. ;cnera introd 1ction 
dorsolateral prefrontal cortex, and cerebellum occur in chronic pain (Apkarian 
et al 2011; DaSilva et al 2008; Geha et al 2008; Gustin et al 2011; Schweinhardt & 
Bushnell 2010; Tracey 2007; 2008; Tracey & Bushnell 2009; Tracey et al 2002). P recise 
phenotypic characterisation and imaging may be used to set objective c riteria with 
which to measure disease and evaluate its t reatment. QST phenotypic characterisation 
aiming to select patients for enrolment into clinical t rials might decrease variance and 
increase the power to detect meaningful drug effects. 
Objectives of this thesis are to investigate: 
1. Implications of QST for clinical neuropathic pain practice: 
a. Are there differences in the diagnostic outcome of sensory signs in 
patients with neuropathic pain assessed by QST and bedside tests? (chapter 2) 
b. Does a g reater level of certainty whether a pain condition is neuropathic 
reflect an increase in numbers of sensory abnormalities or/and specific 
patterns of sensory signs? (chapter 3) 
2. Implications of QST for clinical neuropathic pain research: 
a. Is QST valid to be used as a tool to identify somatosensory homogenous 
groups of patients with neuropathic pain? (chapter 4) 
3. Implications of QST in non-neuropathic pain diseases: 
a. ls QST sensitive to identify pain-contributing somatosensory changes in 
patients with patellar tendinopathies? (chapter 5) 
To address these objectives, a large QST database including healthy volunteers and 
patients with neuropathic pain was established. QST data from neuropathic pain patients 
were compared to those obtained from healthy controls with the aim to gain insight into 
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In patients who experience unilateral chronic pain, abnormal sensory perception at the 
non-painful side has been reported. Contralateral sensory changes in these patients 
have been given little attention, possibly because they are regarded as clinically 
irrelevant. Still, bilateral sensory changes in these patients could become clinically 
relevant if they challenge the correct identification of their sensory dysfunction in terms 
of hyperalgesia and allodynia. Therefore, we have used the standardized quantitative 
sensory testing (QST) protocol of the German Research Network on Neuropathic Pain 
( DFNS) to investigate somatosensory function at the painful side and the corresponding 
non-painful side in unilateral neuropathic pain patients using gender- and age-matched 
healthy volunteers as a reference cohort. 
Sensory abnormalities were observed across all QST parameters at the painful side, but 
also, to a lesser extent , at the contralateral, non-painful side. Simi Jar relative distributions 
regarding sensory loss/gain for non-nociceptive and nociceptive stimuli were found for 
both sides. Once a sensory abnormality for a QST parameter at the affected side was 
observed, the prevalence of an abnormality for the same parameter at the non-affected 
side was as high as 58% (for Pressure Pain Threshold). 
Our results show that bilateral sensory dysfunction in patients with unilateral neuropathic 
pain is more rule than exception. Therefore, this phenomenon should be taken into 
account for appropriate diagnostic evaluation in clinical practice. This is particularly 
true for mechanical stimuli where the 95% Confidence Interval for the prevalence of 
sensory abnormalities at the non-painful side ranges between 35% and 52%. 
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1. Introduction 
In clinical practice, the assessment of chronic pain includes documentation of pain 
location, intensity, quality and onset/duration aimed to elucidate the underlying 
pathophysiological mechanism. Sensory testing is an important part of this assessment 
which is aimed at identifying phenomena such as hyperalgesia (increased response to 
painful stimuli) and allodynia {painful response to normally non-painful stimuli) for 
thermal and mechanical stimuli ( Haanpaa etal 2009). Forth is clinical evaluation, patients 
are generally used as their  own control when comparing profiles of sensory dysfunction 
at the painful side with the contralateral non-painful area ( Haanpaa et al 2009; Walk 
et al 2009). The correct identification of the specifics of sensory dysfunction in each 
chronic pain patient is obviously of major importance for addressing the underlying 
mechanism such as peripheral or spinal hyperexcitability and has consequences for 
pharmacological t reatment. 
There are only a few studies reporting bilateral sensory abnormalities in chronic pain 
conditions. Huge and co-workers, 2008 investigated thermal sensory function at the 
affected and non-affected side of acute and chronic complex regional pain syndrome 
(CR PS) patients and found bilateral sensory changes for both patient groups ( Huge et al 
2008). Another study investigating bilateral warmth/cold detection and heat/cold pain 
thresholds over the hand/wrist in patients with unilateral carpal tunnel syndrome (CTS) 
revealed bilateral thermal hyperalgesia in patients with st rictly unilateral CTS compared 
to controls (de la Llave-Rincon et al 2009). In a similar patient population, Fernandez­
de-las-Pefias and colleagues (2009) reported bilateral pressure pain hyperalgesia in 
patients with unilateral CTS. 
In spite of the studies referred to above, the occurrence of contralateral sensory changes 
in situations where the pain is experienced only unilaterally is still not generally 
acknowledged. Possibly this is because it is regarded clinically i rrelevant. However, 
bilateral sensory changes could become clinically relevant in patients with unilateral 
pain if they challenge the correct qualification of sensory dysfunction. For example, if a 
mechanical stimulus which is known to be slightly painful presented at the non-affected 
and affected side is rated by the patient as equally painful at both sides, one could conclude 
normal sensory functioning. However, ifboth the non-affected and affected side of this 
patient are hyperalgesic for this particular stimulus, the conclusion of a mechanical 
hyperalgesia could be overseen. The German Research Network on Neuropathic Pain 
( DNFS) established a standardized Quantitative Sensory Testing (QST) protocol which 
allows a comprehensive somatosensory characterisation of chronic neuropathic pain 
patients , using reference values from healthy volunteers (Rolke et al 2006a). Since this 
approach does not rely on reference values obtained from the patient's own contralateral 
side, it offers a unique opportunity to study bilateral somatosensory function in patients 
with chronic unilateral pain in a detailed, standardized manner. 
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Based on previous reports we hypothesize that bi lateral somatosensory abnormalities are 
frequently present in unilateral chronic pain patients and that bilateral sensory changes 
may exist for the same QST parameter. To test th is we selected a large cohort of patients 
with unilateral neuropathic pain. We examined the painful side and its corresponding 
contralateral area using the standardized DNFS QST protocol comparing values with 
those obtained from age- and gender-matched healthy volunteers. 
2. Methods 
The study adhered to the declaration of Helsinki was approved by the medical ethical 
committee "Stichting Beoordeling Ethiek Bio-Medisch Onderzoek, P.O. Box 1004, 
9400 BA Assen, The Netherlands", including patients and healthy controls from the 
local region. All participants signed an informed consent form. 
2.1. Description of healthy controls 
In total, 209 age- and gender-matched healthy volunteers (age range 20-73 years), 138 
females (age 45.3 ± 13.4 years) and 71 males (age 48.7 ± 14.0 years) underwent the QST 
assessments on their dorsal hand and foot. These body locations have been indicated 
by Rolke et al., 2006 as reference sites for QST (Rolke et al 2006a). A previous study 
concluded that there were no significant differences in QST parameters between the 
right and left sides of the body in healthy volunteers ( Raike et al 2006a), thus we 
obtained QST reference values from one side of the body. In total, 418 QST references 
from the upper and the lower extremity were obtained. Healthy subjects were identified 
according to medical history. Subjects were specifically questioned about previous 
injuries or diseases. The healthy subjects did not use pain medication regularly and 
were free of medication at the time of the assessments. 
2.2. Description of the patient cohort 
Patients were recruited from the outpatient Department of the Pain Management 
Unit of the University Medical Center Groningen, The Netherlands. A11 patients were 
diagnosed as suffering from neuropathic pain by the physicians of the pain management 
unit. Neuropathic pain diagnosis was made on grounds of coherent patient history, 
medical history, physical examination, including neurologic function tests. Each 
clinical diagnosis was additiona11y confirmed by an experienced pain specialist of the 
Pain Management Unit based on patient's files. In total, 81 neuropathic pain patients 
(43 females age 52.6 ± 12.7 years and 38 males age 49.8 ± 13.0 years) underwent the 
QST assessment, each at the area where the most profound pain was experienced and at 
their contralateral counterpart (leg : n=42, arm : n=l 9, thorax: n=7, groin : n=4, shoulder : 
n=3, back : n=2, neck: n=l ,  abdomen: n=l ,  flank: n=l). 
Prior to undergoing the QST assessments, patients were asked to rate their ongoing 
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pain level using a Numerical Rating Scale (NRS) of 'O' indicating "no pain", and '100' 
indicating "most intense pain imaginable". Patients did not discontinue their regular 
pain treatment if applicable. 
2.3 Quantitative sensory testing (QST) 
The QST battery consisted of seven tests, measuring thirteen parameters and was 
applied according to the standardized protocol of Ro Ike et al., 2006 (Rolke et al 2006a). 
QST was performed by two research nurses, who underwent a comprehensive training 
at the DNFS in Germany. AH  tests were performed at the same research facility of PRA 
Int., Groningen, The Netherlands. The average room temperature was 22.8°C; SD ± 
1.8°C.  
Thermal QST tests were performed using the Medoc Pathway System (Medoc, Israel) 
and consisted of six parameters: threshold assessments for warm and cold detection 
( W OT, C DT) and heat pain and cold pain ( HPT, C PT). In addition, subjects were 
asked about paradoxical heat sensations ( PHS) during the thermal sensory limen (TSL) 
procedure of alternating warm and cold stimuli. 
Mechanical QST tests consisted of seven different parameters. The mechanical 
detection threshold ( MDT) was determined with a standardized set of modified von 
Frey filaments (Optihair2-Set, Marstock Nervtest, Germany). The mechanical pain 
threshold (MPT) was measured using a set of seven pinprick devices (flat contact area 
of0 .2 mm in diameter) with fixed stimulus intensities that exerted forces of 8, 16, 32, 
64, 128, 256, and 512 mN. Mechanical pain sensitivity (MPS) was assessed using the 
same set of seven weighted pinprick stimuli to obtain a stimulus-response function 
for pinprick-evoked pain. Dynamic mechanical a11odynia ( OMA) was assessed  as part 
of the test above, using a set of three light tactile stimulators as dynamic innocuous 
stimuli: cotton wisp, cotton wool tip fixed to an elastic strip and a standardized brush 
(SENSElab No.5, Somedic, Sweden). 
Vibration detection threshold ( VDT) was performed with a Rydel-Seiffer graded 
tuning fork (64 Hz, 8/8 scale) that was placed over a bony prominence. The wind up 
ratio ( W UR) test was assessed with a pinprick intensity of256 mN. The pressure pain 
threshold ( PPT) was determined over muscle with a pressure gauge device (FDN200, 
Wagner Instruments, CT, USA). 
2.4. Data analysis and statistics 
2.4.1. Z-transformation of QST data 
QST data of patients with neuropathic pain were compared with reference data from 
gender and age matched healthy subjects. Both, patients and healthy subjects were 
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divided into two age groups each (20 -45 years of age and 46-75 years of age). QST values 
of chronic pain locations and their mirror image area at the upper ext remities were 
compared  to QST reference values obtained from the dorsal hand of healthy controls 
(n=63 for females and n=29 for males for age group 20-45 years; n=75 for females and 
n=42 for males for age group 46-75 years), whereas values from chronic pain locations 
at lower extremities and thei r mirror image area were compared to reference values 
obtained from the dorsal foot of healthy controls (n=63 for females and n=29 for males 
for  age group 20-25 years; n=75 for females and n=42 for males for age group 46-75 
years). QST values from each patient were t ransformed to z-scores as described by 
Rolke et al., 2006 (Rolke et al 2006a). A score above 1.96 or below -1.96 falls outside the 
95% confidence interval of the mean reference value and was considered as a sensory 
abnormality. Abnormalities were subsequently categorized as either a sensory gain or 
a sensory loss. 
Because "dynamic mechanical allodynia" ( OMA) never occurs in healthy volunteers, 
the QST parameter could not be used for z-score analysis. Alternatively, patients 
ratings greater than NRS 10 (scale 0-100) were regarded as clinica11y relevant and were 
identified as abnormal. 
For the QST parameter "wind up ratio" ( W UR), twenty-three patients (thirteen 
assessments at the affected side and ten assessments at the cont ralateral side) rated 
the single pinprick stimulus as "0" making ratio calculations (painfulness of one 
pinprick stimulation vs. painfulness of a train of ten pinprick stimulations) for Wind-up 
impossible. For these patients W UR was not used for subsequent analyses. 
2.4.2. Proportion of patients with sensory abnormalities at tile affected side 
For each QST parameter, the proportion of patients with sensory abnormalities at the 
painful, affected side was calculated. To estimate the prevalence of sensory abnormalities 
in the general patient population we calculated the 95% confidence intervals of the 
calculated proportions using the 'Wilson Estimate' of proportion (Moore & McCabe 
2003). These 95% confidence intervals give an indication of the expected range of the 
occurrence of abnormalities in the general pain patient population with neuropathic 
pain and tests whether the proportion differs significantly from zero (p<0.05). 
2.4.3. Proportion of patients with sensory abnormalities at tile contralateral side 
For each QST parameter, the proportion of patients with sensory abnormalities at 
the non-painful, contralateral side was calculated applying the same procedure (see 
2.4.2.). 
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2.4.4. Proportion of patients with sensory abnormalities for the same QST parameter 
at the affected and contralateral side 
For each patient, the presence or absence of a sensory abnormality at the contralateral 
side for a particular QST parameter was determined when the patient had already shown 
a sensory abnormality for th is QST parameter at the affected side. Th is allowed the direct 
identification of a relationship between bilateral sensory abnormalities for the same 
QST parameter. To increase statistical power we recalculated the above proportions but 
now pooled the thermal QST parameters (CPT, HPT, W OT, CDT, TSL and P HS) into 
one overall thermal QST domain and pooled the mechanical QST parameters ( WUR, 
MPT, MPS, MDT, VDT, PPT and ALL) into one overall mechanical domain. 
Again we estimated the prevalence of sensory abnormalities in the general patient 
population with the 'Wilson Estimate'. All proportions are reported as percentages. 
2.4.5. Correlation between background pain and sensory abnormalities 
To identify correlations between ongoing background pain and values for each QST 
parameter Pearson correlations were calculated. 
2.4. 6. Correlation between numbers of sensory abnormalities at the affected 
and contralateral side 
The overall numbers of sensory abnormalities for the affected and contralateral side 
across the thirteen QST parameters were compared to identify possible relationships 
using Pearson correlations. 
3. Results 
3.1. QST observations in healthy controls 
From the healthy volunteer cohort (n=209) investigated in this study, a total of 418 
locations were assessed and 5434 measurements were analysed by means of z-score 
profiling. 
3.1.1. Sensory function in healthy controls 
Although the majority of the QST results obtained in healthy subjects confirmed normal 
sensory function for this cohort, incidental sensory abnormalities (4.3%) were observed 
for all QST parameters with the exception of DMA. 
Out of the total of 418 different body areas that were tested across all healthy controls 
62.0% (259 locations) showed normal sensory function and 38.0% (159 locations) 
showed a sensory abnormality for at least one QST parameter. Sensory abnormalities 
were regarded as sensory gain in 20.8%, sensory loss in 12.7% and a mixture of sensory 
gain and sensory loss in 4.5% of the cases ( Fig .2-1). 
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Figure 2-1 : Sensory findings (gain and/or loss of sensory function) in % for healthy controls 
(n=208 with 41 8 test sides) and for patients at the affected and contralateral side (n=81 ). 
"No sensory abnormalities": none of the Quantitative Sensory Testing (QST) parameters were 
outside the 95% Cl. "Only sensory gain": at least one QST parameter indicating thermal or 
mechanical hyperesthesia or hyperalgesia without the presence of hypoesthesia or hypoalgesia. 
"On ly sensory loss": at least one QST parameter indicating thermal or mechanical hypocsthcsia 
or hypoalgesia without the presence of hyperesthesia or hyperalgesia. "Sensory gain and loss": 
at least one positive sign combined with one negative sign. 
3.2. Demographics of patients 
Demographic data of the patients are shown in Table 2-1. All patients reported ongoing 
spontaneous pain only at their affected side ranging from 3 to 90 (Mean 64.1± 21.4 SD) 
on a 0-100 N RS just before the QST assessment took place. The aetiology of patient's 
pain in our sample was quite diverse, but did not include cent ral pain patients. The 
largest subgroups developed pain after a surgical intervention (n=27) including one 
patient with Complex Regional Pain Syndrome- I I  (CRPS) followed by an accident 
with trauma including fractures (n=26). Other patients reported pain after failed back 
surgery (n=8), Herniated nucleus pulposus (n=7), amputation (n=4), radiotherapy (n=3), 
peripheral nerve entrapment (n=2). Three patients were diagnosed with postherpetic 
neura lgia and one patient was with Meralgia paresthetica (see Table 2-1). 
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Table 2-1. Demographics of patients. 
Patient Gender Age Pain Cause of Involved Clinical diagnosis Number of QST Number of QST 
NRS Pain nerve abnormalities at abnormalities at 
(0-100) affected side contralateral side 
F 25 70 Accident with trauma N. digitalis peripheral nerve Injury 3 2 
2 F 39 80 Postsurgical parn N. radialis peripheral nerve injury 1 
41 40 Postsurg1cal parn TH 1 1  peripheral nerve injury 0 
4 F 41 70 Metacarpal fracture N. ulnaris peripheral nerve Injury 0 
5 46 75 Accident with trauma C 6  peripheral nerve injury 1 
6 F 46 85 Postsurgical pain N. digitalis palmaris penpheral nerve injury 2 2 
F 46 40 Amputation N. cutaneous brachii peripheral nerve injury 
8 F 48 60 Accident with trauma N. ulnaris penpheral nerve Injury 0 0 
9 F 51 80 Peripheral nerve entrapment C 6/7 peripheral nerve injury 4 2 
10 F 51 70 Postsurg1cal pain TH 1 1/12 penpheral nerve mjury 2 2 
1 1  F 53 80 Radiotherapy TH 3-TH 6 penpheral nerve Injury 4 3 
12 F 64 60 Accident with trauma TH 9/10 peripheral nerve Injury 3 
1 3  F 66 75 Accident with trauma Cranial nerve XI penpheral nerve Injury 3 2 
14 F 67 85 Herniated nucleus pulposus TH 6/7 peripheral nerve Injury 0 
15  F 71 3 Herpes zoster TH 12  postherpetIc neuralgia 6 
16 F 73 25 Herpes zoster TH 1 1  postherpetIc neuralgia 3 0 
17  F 27 70 Femur fracture N. sapheneus intemus penpheral nerve injury 2 
18  F 36 80 Cruris fracture N. tibialis peripheral nerve inJury 6 
19 F 37 80 Postsurg1cal pain TH 9/10 penpheral nerve mjury 2 3 
20 F 40 70 Amputation N. tibialis penpheral nerve injury 4 
21 F 41 70 Postsurg1cal parn N. peroneus and N. tibialis peripheral nerve injury 4 0 
22 F 42 70 Herniated nucleus pulposus N. peroneus profundus penpheral nerve mJury 4 
23 F 43 75 Accident with trauma N. tibialis peripheral nerve rnJury 4 2 
24 F 43 75 Meralg1a pareslhetica N. femorahs penpheral nerve injury 2 3 
25 F 46 75 Accident with trauma N. peroneal penpheral nerve Injury 2 
26 F 47 80 Accident with trauma L 4  penpheral nerve injury 2 
27 F 49 50 Accident with trauma N. t1b1ahs peripheral nerve mjury 4 
28 F 49 30 Failed back surgery L 5-S 1 peripheral nerve injury 3 
29 F 50 10 Radiotherapy Plexus brach1ahs penpheral nerve injury 3 3 
30 F 52 100 Failed back surgery L 5/6 penpheral nerve injury 3 2 
31 F 55 90 Herniated nucleus pulposus L 5-S 1 penpheral nerve injury 3 2 
32 F 56 90 Postsurg1cal parn N. Suralis penpheral nerve Injury 2 
33 F 58 90 Postsurgical pain N. femorahs penpheral nerve injury 2 
34 F 59 60 Postsurgical pain N. plantaris peripheral nerve injury 
35 F 61 80 Postsurgical pain L 4/5 peripheral nerve injury 2 3 
36 F 62 80 Failed back surgery L 5-S 1 peripheral nerve injury 6 0 
37 F 65 70 Herniated nucleus pulposus L 5-S 1 penpheral nerve injury 6 
38 F 65 50 Amputation Peroneal nerves peripheral nerve injury 7 
39 F 66 70 Postsurgical pain N. peroneus penpheral nerve injury 2 
40 F 66 90 Postsurgical pain N. lib1ahs peripheral nerve injury 5 
41 F 71 65 Failed back surgery L 5-S 1 penpheral nerve injury 3 2 
42 F 72 80 Failed back surgery L 4/5 penpheral nerve injury 2 
43 F 75 80 Herniated nucleus pulposus L 4/5 peripheral nerve mJury 4 2 
44 M 23 70 Postsurgical pain TH 8/9 penpheral nerve injury 2 2 
45 M 26 85 Accident with trauma C B  peripheral nerve mjury 
46 M 32 40 Postsurgical pain TH 1 1  penpheral nerve injury 4 
47 M 38 90 Accident with trauma N. brach1ahs peripheral nerve injury 6 
48 M 47 80 Accident with trauma L 4/5 peripheral nerve injury 8 5 
49 M 42 70 Failed back surgery L 5/6 penpheral nerve mjury 7 2 
50 M 43 90 Postsurgical pain TH 10 /12 penpheral nerve mjury 6 
51 M 49 40 Accident with trauma N. ulnaris peripheral nerve injury 2 1 
52 M 50 70 Radiotherapy TH 2 penpheral nerve injury 4 
53 M 50 75 Rib fracture TH 1 1  peripheral nerve injury 6 2 
54 M 52 55 Postsurg1cal pain N ulnans CRPSII 2 2 
55 M 53 45 Accident with trauma N. ulnaris peripheral nerve mjury 2 2 
56 M 55 50 Accident with trauma N. rad1ahs peripheral nerve mJury 2 
57 M 56 55 Postsurg1cal pam N. aXJllans peripheral nerve injury 1 
58 M 58 40 Herniated nucleus pulposus C 5-C 7 peripheral nerve Injury 0 0 
59 M 58 80 Postsurgical pain N. radialis peripheral nerve injury 1 
60 M 59 60 Accident with trauma N rad1alis peripheral nerve injury 2 
61 M 60 80 Postsurg1cal pain C 4  peripheral nerve mjury 0 
62 M 63 65 ACCJdent with trauma N digib penpheral nerve injury 0 0 
to be continued on page 34 
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Table 2-/. Demographics of patients. 




















NRS Pain nerve abnonnalities at abnormalities at 
(0-100) affected side contralateral side 
M 73 10  Herpes z:oster TH 8 postherpetic neuralgia 0 
M 24 50 Postsurgical pain N .  llioinguinalis peripheral nerve inJury 
M 28 75 Postsurg1cal pain N. tibialis peripheral nerve injury 
M 40 60 Amputation N. plantaris penpheral nerve injury 
M 41 3 Failed back surgery S 1 peripheral nerve injury 4 
M 43 60 Accident with trauma L 4  penpheral nerve injury 4 
M 44 40 Accident with trauma N. femoralis peripheral nerve injury 1 0 
M 44 35 Postsurgical pain N .  llioinguinalis peripheral nerve injury 2 0 
M 46 65 Failed back surgery L 4/5 peripheral nerve injury 0 
M 47 75 Postsurgical pain N .  tibialis peripheral nerve injury 4 
M 51 70 Postsurg1cal pain N. femoralis peripheral nerve injury 0 
M 53 70 Accident with trauma L 5  peripheral nerve injury 0 0 
M 54 50 Postsurgical pain N. grenito-femoralis peripheral nerve injury 0 
M 57 75 T1b1a fracture N. tibialis peripheral nerve injury 5 4 
M 62 70 Accident with trauma N. peroneus peripheral nerve injury 2 
M 63 BO Postsurg1cal pain N. saphenus peripheral nerve injury 1 
M 65 65 Herniated nucleus pulposus L 5  peripheral nerve injury 5 4 
M 73 10  Peripheral nerve entrapment L 5-S 1 peripheral nerve injury 3 2 
M 75 60 Postsurgical pain N. tibialis peripheral nerve injury 2 
Demographic patient overview; Patient ID, gender and age are indicated. Patient's rating of ongoing 
pain prior to Quantitative Sensory Testing (QST) using a Numeric Rating scale (NRS) indicating "O" 
as "no pain" and " 1 00" as the "most intense pain imaginable" .  Involved nerve indicates nerves (N.) 
or innervations area of nerves affected in relation to the cause of pain. Number of QST abnormalities 
refers to the number of QST parameter exceeding CI 95% of z-scores at the affected and contralateral 
side. 
3.3. QST observations in patients 
For the 81 patients investigated in this study, 2106 QST data measurements were 
obtained from both the affected and contralateral side. The total of 2083 measurements 
were analysed by means of z-score profiling. 
3.3.1. Sensory function in patients 
In patients with neuropathic pain, sensory abnormalities were observed in all QST 
parameters at both affected and contralateral side (Fig. 2-2). In our patient cohort, 
91 % had at least one QST abnormality at the affected side. Of the patients without 
sensory abnormalities at the affected side (9%), 14% still showed at least one sensory 
abnormality at the contralateral side. At the affected side, 50% of the patients had a 
mixture of sensory gain and loss , 31 % had only sensory gain (hyperalgesia), and 10% 
had only sensory loss (hypesthesia) (Fig. 2-1 ). 
At the contralateral side, 78% of the patients had at least one QST abnormality. In 
26% of the patients a mixture of sensory gain and loss was present. Almost 36% of the 
patients showed only sensory gain and 16% had only sensory loss at the contralateral 
side (Fig. 2-1 ). 
2 .  Bilateral abnormalities in neuropathic pain 95% Confidence Intervals confirmed that the prevalence of normal sensory function differs significantly between healthy controls and patients at the painful and non-painful side (all p<0.05). A significant difference was also present between the painful side and non-painful side of the patients (p<0.05). 
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PPT • Fig. 2-2: Z-score profile for each Quantitative Sensory Testing (QST) parameter at the affected side (left) and contralateral side (right) in 81 neuropathic pain patients. Gray shade indicates normative data with 95% CI obtained from healthy references. A Z-score exceeding the upper or lower bound of CI 95% is regarded as a significant gain or loss of function, respectively. QST parameters: Cold Pain Threshold (CPT), Heat Pain Threshold (HPT), Warm Detection Threshold (WOT), Wind Up Ratio (WUR), Cold Detection Threshold (CDT), Thermal Sensory Limen (TSL), Paradoxical Heat Sensation (PHS), Mechanical Pain Threshold (MPT), Mechanical Pain Sensitivity (MPS), Mechanical Detection Threshold (MDT), Vibration Disappearance Threshold (VDT), Pressure Pain Threshold (PPT). 8 ► 
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3.3.2. Sensory changes at patients affected side Sensory abnormalities at the affected side ranged from 7.4% (n=S) for WUR to 48. 1 % (n=39) for PPT. 95% Confidence Intervals confirmed that the prevalence differed significantly from zero (p<0.05) for all QST parameters with highest incidence for MPT (95CI: 27%-48%) and PPT (95CI: 38%-59%) (Table 2-2A). For the nociceptive parameters (CPT, HPT, PPT, MPS, WUR) there were predominantly changes reflecting hyperalgesia, whereas for the non-nociceptive ones (CDT, WDT, TSL, MDT, VDT) they reflected hypesthesia (Fig. 2-3). 
Table 2-2A and 2-2B: Overview of sensory abnormalities in QST 
2A 
QST parameter affected side CPT HPT WOT WUR CDT TSL PHS MPT MPS MDT VDT PPT OMA 
n of sensory abnormality 7 1 1  1 7  5 20 21 20 30 20 25 19 39 16 
n of sensory gain 7 1 1  3 4 1 1 20 6 20 2 1 39 16 
n of sensory loss 0 0 14 1 1 9  20 0 24 0 23 18 0 0 
% of sensory abnormality 8,6 1 3,6 21 ,0 7,4 24,7 25,9 24,7 37,0 24,7 30,9 23,5 48,1 19,8 
Wilson estimates lower Cl 95% 4,0 7,6 13,5 2,9 16,6 17,6 16,6 27,3 16,6 21 ,9 15,5 37,6 12,5 
Wilson estimates upper Cl 95% 17,1 22,9 31 ,2 16,6 35,2 36,5 35,2 47,9 35,2 41 ,7 33,9 58,9 29,9 
p<0.05 
2B 
QST parameter contralateral side CPT HPT WOT WUR CDT TSL PHS MPT MPS MDT VDT PPT OMA 
n of sensory abnormality 1 9 9 7 12  12 9 1 5  1 1  1 0  9 24 3 
n of sensory gain 1 9 5 7 2 5 9 2 9 2 0 24 3 
n of sensory loss 0 0 4 0 1 0  7 0 1 3  2 8 9 0 0 
% of sensory abnormality 1,2 1 1 , 1  1 1 , 1  9,9 14,8 14,8 1 1 . 1  18,5 13,6 12,3 1 1 , 1  29,6 3,7 
Wilson estimates lower Cl 95% -0,4 5,8 5,8 4,6 8,6 8,6 5,8 1 1 ,5 7,6 6,7 5,8 20,8 0,9 
Wilson estimates upper Cl 95% 7,5 20,1 20,1 19,4 24,4 24,4 20,1 28,5 22,9 21 ,5 20,1 40,4 1 0,9 
p<0,05 n.s. Patient numbers with sensory abnormalities at the affected (Table 2-2A, top) and contralateral side (Table 2-2B, bottom). Shown are direction (n of sensory gain / n of sensory loss) and overall abnormalities in percent (% of sensory abnormality) for each Quantitative Sensory Testing (QST) parameters in 81 chronic pain patients. QST parameter: Cold Pain Threshold (CPT), Heat Pain Threshold (HPT), Warm Detection Threshold (WDT), Wind Up Ratio (WUR), Cold Detection Threshold (CDT), Thermal Sensory Limen (TSL), Paradoxical Heat Sensation (PHS), Mechanical Pain Threshold (MPT), Mechanical Pain Sensitivity (MPS), Mechanical Detection Threshold (MDT), Vibration Disappearance Threshold (VDT), Pressure Pain Threshold (PPT) and Dynamic Mechanical Allodynia (DMA). Wilson estimates with upper and lower bound of the 95% CI for each QST parameter (* p<0.05); n.s. indicates not significant. For the nociceptive parameters CPT and HPT, thermal pain threshold were decreased indicating a thermal hyperalgesia. An increased pain due to blunt pressure (PPT) and an increased sensitivity to mechanical pain (MPS) were observed indicating only hyperalgesia for these parameters. For MPT a greater incidence for mechanical hypo­than hypersensitivity was detected. WUR was more frequently increased than decreased indicating a greater incidence for hyper- than hyposensitivity. 
36 
2 .. B i : '  tcra abnor naHties i 1 .  curopathic pa in  
Thermal hypesthesias were observed also in most of the patients for CDT, WDT and 
TSL .  For MDT there was predominantly a sensory loss observed indicating a mechanical 
hypesthesia . It was possible to detect hyperesthesia for VDT for one patient, but for the 
large majority VDT responses indicated hypesthesia . 
In 25% (n=20) of the patients a sensory gain for PHS was detected at the affected side . 
OMA was present in 26% of the patients, in 6% of very mild intensity, however, 20% 
of patients showed a clinical relevant increased response for OMA indicating a dynamic 
allodynia . 
3.3.3. Sensory changes at the patient 's contralateral side 
Sensory abnormalities at the contralateral side ranged from 1.2% (n= l)  for CPT to 
29 .6% (n=24) for PPT .  With the exception of CPT, 95% Confidence Intervals confirmed 
that the prevalence differed significantly from zero (p<0 .05) for all QST parameters 
with highest incidence for MPT (95C I: 12%-29%) and PPT (95C I: 21%-40%) ( Table 
2-2B). 
Overall there were less sensory abnormalities at the contralateral side than at the affected 
side . 
For nociceptive parameters there was predominantly sensory gain observed, suggesting 
the presence of hyperalgesia, whereas for non-nociceptive parameters predominantly a 
sensory loss was i dentified suggesting hypesthesia (Fig . 2-3). 
Only sensory gain for CPT, HPT, PPT and W UR were observed suggesting hyperalgesia . 
For MPT sensory loss was more frequently observed than sensory gain indicating a 
greater incidence for mechanical hyposensitivity than hypersensitivity. In contrast, for 
MPS was sensory gain was more frequently observed than sensory loss indicating a 
greater incidence for mechanical hypersensitivity than hyposensitivity. 
Thermal hypesthesias were observed for most of the cases for CDT and for TSL, only 
6.2% of patients showed hyperesthesia for TSL and 2.5% for CDT. W OT abnormalities 
were observed in 11.0% of the cases and this was due to both sensory loss and gain . For 
MDT at the contralateral side sensory loss was observed twice as often as sensory gain, 
indicating a greater incidence for mechanical hypesthesia . There was only hypesthesia 
for VDT at the contralateral side. 
In 11.1 % of the patients a sensory gain for P HS at the contralateral side was detected .  
DMA was present in 19 . 8% of patients, but mostly of very mild intensity. However, 3. 7% 
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Fig 2-3 : Quantitative Sensory Testing (QST) z-score abnormalities in % at the affected ( left) 
and contralateral side (right) in 8 1  neuropathic pain patients. QST parameter are ordered as sensory 
parameters: Cold Detection Threshold (CDT), Warm Detection Threshold (WOT), Thermal Sensory 
Limen (TSL), Mechanical Detection Threshold (MDT), Vibration Disappearance Threshold (VDT), 
Paradoxical Heat Sensation (PHS), Dynamic Mechanical Allodynia (OMA) and nociceptive 
parameters : Cold Pain Threshold (CPT), Heat Pain Threshold (HPT), Pressure Pain Threshold (PPT), 
Mechanical Pain Threshold (MPT), Mechanical Pain Sensitivity (MPS) and Wind Up Ratio (WUR). 
Z-scores with positive sensory signs (gain of sensory function) plotted rightwards and negative 
sensory signs ( loss of sensory function) plotted leftwards. Absence of OMA is normal and therefore 
no negative sign possible. 
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Table 2-3: Overview of sensory abnormalities at the contralateral side given an abnormality at the affected side 
OST parameter CPT HPT WOT WUR CDT TSL PHS MPT MPS MDT VDT PPT OMA 
n of sensory gain similar to affected side 1 2 2 0 1 6 0 8 0 0 23 2 
n of sensory loss similar to affected side 0 3 0 6 3 0 8 0 6 8 0 0 
% of sensory abnorrnaijty similar to affected side 27,3 40,0 33,3 50,0 34,8 25,0 33,3 29,4 41,7 29,6 45,5 58,1 20,0 
Wilson estimates lower Cl 95% 1 ,0 15,2 13,2 15.4 15,3 8,0 14,5 14,1 21,9 12,4 24,6 43,4 2,5 
Wilson estimates upper Cl 95% 53,6 64,8 53,5 84,6 54,2 42,0 52,2 44,7 61,4 46,9 66,3 72,9 37,5 
p<0.05 
Percent (% of sensory abnormality) indicates overall occurrence of sensory abnormalities for 
each Quantitative Sensory Testing (QST) parameter at the contralateral side once there was already 
an abnormality for the same parameter detected at the affected side in 81 chronic pain patients. QST 
parameters: Cold Pain Threshold (CPT), Heat Pain Threshold (HPT), Warm Detection Threshold 
(WOT), Wind Up Ratio (WUR), Cold Detection Threshold (CDT), Thermal Sensory Limen {TSL), 
Paradoxical Heat Sensation (PHS), Mechanical Pain Threshold (MPT), Mechanical Pain Sensitivity 
(MPS), Mechanical Detection Threshold (MDT), Vibration Disappearance Threshold (VDT), 
Pressure Pain Threshold (PPT) and Dynamic Mechanical Al lodynia (OMA). Wi lson estimates with 
upper and lower bound of the 95% Cl for each QST parameter (* p<0.05). 
3.3.3. 1. Example of magnitude of somatosensory abnormalities 
Here we describe one patient in greater detail for better understanding of the magnitude 
of somatosensory abnormalities based on raw values of the QST battery. 
A 25 year old woman ( ID 1) suffered from a cut injury at her left hand with a lesion of the 
digitalis nerve. Subsequently, she developed severe pain at left palm including digits IV  
and V. Bedside tests using von Frey filaments and a brush confirmed impaired sensibility 
including allodynia of left hand. These sensory signs were within neuroanatomical 
plausible distribution of the digitalis nerve. The clinical diagnosis "peripheral nerve 
injury" was made. The QST assessment took place in the area of greatest pain complaints 
and on the same contralateral site. Normative data obtained from dorsal hand were 
from 63 age- and gender matched subject's ± SD indicated in brackets. For the affected 
side the patient rated the different pinprick forces with a NRS score of 53. 1 indicating 
an increased sensitivity for mechanical pain (MPS) (0.62 ± 1.00). The NRS ratio for 
Wind up ( WUR) test was increased to 6.5 suggesting central sensitisation (NRS 2.53 
± 2.33). Her ratings for OMA pain of NRS 54. 7 indicated allodynia. Clinically, this 
QST profile indicates a predominant gain of sensory function due to small and large 
fibre sensitisation. At the contralateral side the patient displayed a decreased threshold 
for MDT of 0.5mN (2.22 ± 2.27 mN) and a decreased threshold for CDT of 24.9 ° C 
(30.7 ± 0.77 ° C). OMA pain ofNRS 3.5 indicates minor allodynia. Clinically, for the 
contralateral side a predominant gain of sensory function was found indicating small 
and large fibre sensitisation. 
3.3.4. Sensory changes at the contralateral side in relation to sensory changes 
at the affected side 
To further investigate the extent of contralateral abnormalities we determined the 
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presence or absence of abnormalities in each of the QST parameters at the contralateral 
side given that an abnormality for the same parameter was present at the affected side 
( Table 2-3). This occurred in 20% ( for OMA) to 58% (for PPT) of the cases (Fig. 2-
4). Confidence Intervals (95%) confirmed the prevalence to be significantly (p<0.05) 
different from zero for all QST parameters (see Table 2-3). The highest proportions 
were seen for the VDT (95C I: 25%-66%) and PPT (95C I: 43%-73%). Although all 
proportions were significant, some confidence intervals were very large due to small 
numbers of observations. This was especially true for W UR and for most of the thermal 
QST parameters.  
To increase statistical power with the purpose to allow a more accurate estimation of 
the prevalence of sensory abnormalities in the general chronic pain patient population, 
thermal and mechanical QST parameters were combined into one thermal and one 
mechanical domain. For the affected side this grouping resulted in 20.0% (95CI: 16%-
23%) thermal abnormalities and 27.9% (95C I: 24%-31 %) mechanical abnormalities. 
For the contralateral side 11.0% (95CI: 8%-14%) thermal abnormalities and 14.4% 
(95CI: 11 %-17%) mechanical abnormalities were found. To investigate the occurrence 
of bilateral manifestations of sensory abnormalities we calculated the prevalence of 
thermal and mechanical abnormalities at the contralateral side given that there was an 
abnormality at the affected side for the same QST domain in the same patient. This 
resulted in 95% C I  's for bilateral abnormality ranging from 14%-28% and 35%-52% for 
thermal and mechanical QST domains, respectively. 
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Fig. 2-4: Incidence of QST abnormalities at the contralateral side in 8 1  neuropathic pain patients 
Sensory abnormality in percent (%) of either gain or loss of function for each Quantitative Sensory 
Testing (QST) parameter at the contralateral side once there was already an abnormality detected for 
the same parameter at the affected side. QST parameter in this radar diagram are ordered as 
mechanical stimuli consisting of Mechanical Pain Threshold (MPT), Dynamic Mechanical Al lodynia 
(OMA), Pressure Pain Threshold (PPT), Vibration Disappearance Threshold (VDT), Mechanical 
Detection Threshold (MDT), Mechanical Pain Sensitivity (MPS) and Wind Up Ratio (WUR) 
(left side) and thermal stimuli consisting of Cold Pain Threshold (CPT), Heat Pain Threshold (HPT), 
Warm Detection Threshold (WOT), Cold Detection Threshold (CDT), Thermal Sensory Limen (TSL), 
Paradoxical Heat Sensation (PHS) (right side). 
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3.3.5. Correlation between background pain and QST parameters 
All patients reported ongoing spontaneous pain (NRS mean 64.1, S D ± 21.4) at their 
affected side before the QST assessment took place (see Table 2-1 ). There were no 
significant correlations found using Pearson correlations between background pain 
and QST parameters. A significant correlation was found between the frequencies of 
sensory abnormalities at the contralateral side with background pain (r=0.231; p<0.05). 
Furthermore, this effect was supported by the correlation between the increase of sensory 
gain at the contralateral side and background pain (r=0.270; p=0.015). 
3.3. 6. Correlation between numbers of sensory abnormalities at the affected 
and contralateral side 
The number of sensory abnormalities for patients varied between 0 and 8 for the 
affected and 0 and 6 for the contralateral side for the thirteen QST parameters assessed 
(see Table 2-1 ). The overall occurrence of contralateral abnormalities were significantly 
correlated with abnormalities at the affected side (r=0.31 0; p<0.0 1 ). Furthermore, a 
modest correlation was observed between the presence of sensory loss at the affected 
and contralateral side (r=0.400; p<0.0 1 ), whereas for the presence of sensory gain at the 
affected and contralateral side a stronger correlation was found ( r=0.483; p<0.0 1 ). 
4. Discussion 
This QST study shows that patients with unilateral neuropathic pain have a diversity of 
sensory abnormalities at the painful side, and to a lesser extent, at the contralateral non­
painful side. Using the standardized QST protocol with 13 different parameters to obtain 
a complete sensory profile, it was demonstrated that bilateral sensory abnormalities are 
apparent in a considerable number of the patients that experience chronic unilateral 
pain. 
There was a significant correlation between the number of abnormalities at the painful 
side and the contralateral side. Even more so, if a particular abnormality was detected 
at the painful side this abnormality was then the most likely abnormality to occur 
contralaterally. This was particularly striking for the group of mechanical stimuli where 
the estimated prevalence of sensory abnormalities at the non-painful side was 35%-52% 
(95% Cl) in case a mechanical abnormality was detected at the painful side. These results 
have implications for the evaluation of patients in clinical practice, since often the non­
affected side is used as the reference side. Our results show that using the contralateral 
side as the reference to identify sensory abnormalities at the affected side might lead to 
misinterpretation of the clinical manifestation. 
4.1. Somatosensory function in healthy controls 
Z-score transformation of QST data revealed one or more somatosensory abnormalities 
in 38% ofall members of the healthy control group. This number is in line with previous 
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findings reporting 41 % abnormalities using the QST protocol (Maier et al 2010). 
In our healthy volunteers , abnormalities were observed across all QST parameters with 
the exception of OMA. The detected sensory abnormalities reflected gain of function 
for the most part, some loss of function and in a minority fraction both gain and loss of 
function (Fig 2-1 ). 
Although previously reported otherwise (Maier et al 2010), in the present study, P HS 
> 1 occurred in 1 .4% at the test side "dorsal hand" and in 9 .3% at the test side "dorsal 
foot" . The presence of abnormal PHS in our study could be associated with a greater 
likelihood of sensory dysfunction with an increase in age (r=0.193; p<0.0 1 ). 
4.2. Sensory signs at the affected, painful side of neuropat/1ic pain patients 
As expected,  the large majority (91 %) of neuropathic pain patients showed sensory 
abnormalities at their affected side. Maier and colleagues (2010) (Maier et al 2010) 
reported a similar percentage (92%) of patients with at least one QST abnormality. 
Given the fact that for 9% of the patients , no abnormality could be detected, QST and 
the cut-off of 95% C I  of the mean reference values might possibly be more stringent 
than clinical examination. 
In accordance with previous studies, sensory loss was predominantly found in non­
nociceptive parameters (Maier et al 201 0; Scholz et al 2009) which could be associated 
with central or peripheral neuronal damage which might lead to ongoing pain via 
increased ectopic activity ( Liu et al 2000; Ochoa et al 2005; Serra et al 2009). Sensory 
gain was predominantly found in nociceptive parameters which could be associated with 
peripheral sensitisation and/or altered central processing (Baron 2000; Baumgartner et 
al 2002; Sandkuhler 2009; Treede et al 1992; Wasner et al 2004). 
Maier and co-workers (2010) (Maier et al 2010) reported abnormal QST values for 
the affected side across the different clinical neuropathic pain entities ranging between 
8%-36% (compared to 7%-48% in this study). There was good agreement between our 
estimates of the expected range of sensory abnormalities in the general neuropathic pain 
patient population and those reported by Maier (Maier et al 2010). Only estimate ranges 
for the occurrence of sensory abnormalities for C DT, HPT, TSL, MDT, VDT and CPT in 
the present study differed slightly but were still in close proximity to the values reported 
previously (Maier et  al  2010). 
4.3. Contralateral sensory signs in neuropathic pain patients 
Contralateral sensory changes in patients with chronic pain have been acknowledged 
in a number of clinical studies (Baron & Saguer 1994; de la Llave-Rincon et al 2009; 
Fernandez-de-las-Penas et al 2009; Huge et al 2008; Maleki et al 2000; Oaklander et 
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al 1998; Shenker et al 2008). For instance it was reported that 5% of the patients with 
complex regional pain syndrome (CRPS) present bilateral symptoms ( Veldman & Goris 
1996). Despite reports of the existence of bilateral changes in chronic pain patients 
no elaborate quantitative data have been published. In the present QST study, sensory 
abnormalities at the contralateral side were observed for all QST parameters. 
Comparing the overall sensory findings from the contralateral side with those obtained 
from the healthy controls, a significant difference was shown indicating abnormal 
sensory function at the contralateral side in patients with unilateral neuropathic pain. 
In addition, a significant correlation was found for abnormal sensory function at the 
contralateral sides compared to the affected side. The pattern of sensory abnormalities 
for nociceptive and non-nociceptive parameters at the contralateral side was in line with 
that at the affected side but less severe. All patients had unilateral pain causing event and 
most showed bilateral sensory abnormalities. This finding points at a central component 
in processing the pain and controlling sensory function bilaterally. 
Preclinical studies have also found evidence for bilateral sensory changes upon unilateral 
induction of pain and these studies correlated the severity of pain with occurrence of 
bilateral changes. Hubbard and colleagues (2008) demonstrated in a rat model using 
painful cervical nerve root compression that the occurrence of contralateral allodynia 
depended on the load of compression ( Hubbard & Winkelstein 2008). In another study, 
zymosan induced sciatic neuritis in rats, causing a dose-dependent bilateral allodynia 
(Chacur et al 2001 ). 
In healthy volunteers and patients with rheumatoid arthritis an intradermal administration 
of capsaicin induced mechanical hyperalgesia and allodynia at the side contralateral to the 
injection area (Shenker et al 2008). Studies using capsaicin revealed that short-lasting but 
high intensity pain induces contralateral sensory changes [7; 21 ]. These results suggest 
that pain intensity may play a prominent role in contralateral sensory changes. Potential 
underlying conditions which may lead to contralateral sensory changes in unilateral 
pain condition are currently investigated. Koltzenburg et al. ( Koltzenburg et al 1999) 
suggested the involvement of nerve growth factors (NGF) to explain the contralateral 
peripheral responses in rats with unilateral neural injuries. Other studies suggested the 
involvement of altered glial activation and spinal pro-inflammatory cytokines (tumour 
necrosis factor (TNF), interleukin-1 ( IL-1 ), interleukin-6 ( I L-6)) (Gao et al 2010; 
Hansson 2006; Milligan et al 2003; Watkins & Maier 2002). 
In line with these findings, in the present study we have also found a significant correlation 
between background pain and QST abnormalities at the contralateral side in patients 
who experienced a unilateral pain-causing event. This supports previous suggestions 
that high pain intensity can induce sensory abnormalities at the contralateral side in 
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patients with unilateral pain. Additional studies are needed to evaluate for instance if 
the severity of pain determines the onset of contralateral changes and if ongoing pain 
is the driving force for the maintenance of contralateral abnormalities in chronic pain 
patients. 
4.4. Correlation between sensory changes at affected and contralateral side 
An interesting finding is that the presence of sensory gain or loss at the affected side 
was related to sensory gain or loss for the same QST parameter at the contralateral 
side, ranging from 25% to 58% dependent on the QST parameter. In particular for the 
group of mechanical stimuli the estimated presence of sensory abnormalities at the non­
affected side was substantial (ranging from 35%-52%). Although sensory abnormalities 
at the contralateral side were less pronounced compared to those at the affected side, 
there was a significant correlation between the numbers of sensory abnormalities at both 
sides in patients. 
Contrary to recommendations to use the contralateral side as a reference to identify 
sensory abnormalities in patients ( Haanpaa et al 201 0; Haanpaa et al 2009) our data 
indicate that this is not advisable since the sensory function at the contralateral side 
stands a reasonable chance to be altered. The interpretation of sensory signs and its 
clinical manifestations using the contralateral side or reference values from healthy 
subjects may vary (see Table 2-4 for examples). 
Table 2-4: Diagnostic consequence of using either the contralateral side or normative data from healthy volunteers. 
The difference between the last two columns shows that the choice of reference is not trivial and that using the contralateral 
side in the same patient can lead to misinterpretation of sensory function. 
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observation observation 
affected side contralateral side 
0 0 + 0 
0 
0 + 
0 + + + + clinical result using contralateral side as reference 0 + + 0 ++ 
0 
clinical result using 
healthy volunteers as 
reference 
0 + 0 
0 + + 
The interpretation of sensory function and its clinical manifestation at the affected side using the 
contralateral side or reference values from healthy subjects. The observation at the affected side 
and contralateral side indicate the sensory response for a Quantitative Sensory Testing (QST) 
parameter in patients. Clinical results using the contralateral side as reference or healthy volunteers 
as reference indicate sensory interpretation for the affected side. 'O'  indicate normal sensory function, 
'+' indicate sensory gain such as hyperalgesia/allodynia, '-' indicate sensory loss such as hypesthesia, 
'++' or '- -' indicate overestimation of sensory gain or sensory loss, respectively. 
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Since most (n=77) patients in the present study continued their pain medication i t  cannot 
be excluded that the medication itself might have influenced the onset or maintenance 
of somatosensory changes seen bilaterally. 
These results firmly establish evidence for a cautious use of the contralateral side as a 
reference site in clinical practice. A way to overcome this problem is the use ofreference 
values for either normative response or for pathological response to QST parameters to 
allow a precise identification of sensory abnormalities in patients. 
In conclusion, our data provide detailed evidence for bilateral sensory abnormalities 
in unilateral neuropathic pain patients using a standardized, elaborate QST protocol. 
Our results show that in these patients , the contralateral side should not be regarded as 
normal or healthy per se. This has implications for appropriate diagnostic evaluation in 
clinical practice. 
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Somatosensory profiles but not numbers 
of somatosensory abnormalities of neuropathic 
pain patients correspond with neuropathic 
pain grading 
Konopka K.H., Harbers M., Houghton A., Kortekaas R., van Vliet A., 




Due to the lack of a specific diagnostic tool a grading system to categorize pain 
as 'definite', 'probable', 'possible' a nd 'unlikely' neuropathic pain was proposed. 
Somatosensory abnormalities are common in neuropathic pain and it has been suggested 
that a greater number of abnormalities would be present i n  patients with 'probable' and 
'definite' grades. To test this hypothesis, we investigated the presence of somatosensory 
abnormalities by means of QST in patients with a clinical diagnosis ofneuropathic pain 
and correlated the number of sensory abnormalities and sensory profiles to the different 
grades. 
Of patients who were clinically diagnosed with neuropathic pain, only 60% were graded 
as 'definite' or 'probable', while 40% were graded as 'possible' or 'unlikely' neuropathic 
pain. Apparently, there is a mismatch between a clinical neuropathic pain diagnosis 
and neuropathic pain grading. Contrary to the expectation, patients with 'probable' 
and 'definite' grades did not have a greater number of abnormalities. Instead, similar 
numbers of somatosensory abnormalities were identified for each grade. The profiles 
of sensory signs in 'definite' and 'probable' neuropathic pain were not significantly 
different, but different from the 'unlikely' grade. This latter difference was due to a 
different frequency of a mixture of sensory gain and loss and of sensory loss only. 
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The grading system allows a separation of neuropathic and non-neuropathic pain based 
on profiles but not on the total amount of sensory abnormalities. Our findings indicate 
that patient selection based on grading of neuropathic pain may provide advantages 
iselecting homogenous groups for clinical research. 
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1. Introduction 
The International Association for the Study of Pain ( IASP) defined neuropathic pain 
as a direct consequence of a lesion or disease affecting the somatosensory system 
(Treede et al 2008). Neuropathic pain has traditionally been classified based on the 
underlying aetiology ( Hansson 2003); (2001); ( Woolf & Mannion 1999). Due to the 
lack of a specific diagnostic tool for neuropathic pain, a grading system of 'definite', 
'probable', 'possible' and 'unlikely' neuropathic pain was proposed (Treede et al 2008). 
This grading system aims to determine with a greater level of certainty whether a pain 
condition is neuropathic, especially when including patient's in clinical trials. Briefly, 
the grade 'unlikely' is applicable when patients lack a history of a lesion or disease 
with a plausible neuroanatomical distribution of their pains. The grade 'possible' 
could be regarded as a working hypothesis, which does not exclude, neither diagnoses 
neuropathic pain. Patients who fall into the category 'possible' neuropathic pain can be 
transferred into the grades 'probable' and 'definite' if neurologic examination and the 
presence of a positive confirmatory test reveal confirmatory evidence. 
Although the proposed grading system is intended for clinical and research purposes 
and has been available for several years, studies investigating somatosensory similarities 
between the clinical neuropathic pain entities and the new grading system in large 
patient cohorts are not available. Quantitative sensory testing (QST) has been used to 
identify somatosensory abnormalities in patients with neuropathic pain. The ultimate 
goal of identifying differences in the response to sensory stimuli in neuropathic pain 
patients is the identification of differences in the mechanisms responsible for generating 
sensory abnormalities and their subsequent mechanism-based therapy. A recent QST 
study showed that specific profiles (along thirteen different QST parameters) correspond 
to the different clinical entities of neuropathic pain (Maier et al 2010). The authors 
suggested that in case of a patient showing many sensory abnormalities, the grading of 
this patient would fulfil the criteria for 'probable' or 'definite' neuropathic pain. 
Previously, we showed that bilateral somatosensory abnormalities were common in 
patients with unilateral neuropathic pain ( Konopka et al) (submitted). We did not 
account differences in the quantities of sensory abnormalities at the affected side 
between the clinical entities of neuropathic pain of our study population. In the present 
study, we hypothesized that the number of somatosensory abnormalities in patients 
with clinically diagnosed neuropathy do not differ within the 'definite', 'probable', 
'possible' and 'unlikely' neuropathic pain grading groups. We also aimed to find QST 
profile - based corroboration of the new grading system. 
We selected a large cohort of patients with clinically conf irmed neuropathic pain and 
subsequently categorized each patient according to the neuropathic pain grading. We 
examined the painful area using the standardized (German Research Network on 
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Neuropathic Pain) DNFS QST protocol comparing values with those obtained from 
age- and gender-matched healthy volunteers. 
2. Methods 
The study adhered to the declaration of Helsinki was approved by the medical ethical 
committee "Stichting Beoordeling Ethiek Bio -Medisch Onderzoek, P.O. Box 1004, 
9400 BA Assen, The Netherlands". The study includes patients and healthy controls 
from the local region. All participants signed an informed consent form. 
2.1. Description of healthy controls 
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Healthy subjects were identified according to medical history. Subjects were specifical ly 
questioned regarding previous injuries or diseases. The healthy subjects did not use 
analgesics regularly and were free of medication at the time of the assessments. In 
total , 209 age- and gender-matched healthy volunteers (age range 20-73 years), of which 
138 females (age 45.3 ± 13.4 years) and 7 1  males (age 48.7 ± 14.0 years) underwent 
QST assessments on both, the dorsal hand and foot. These body locations have been 
proposed as reference sites for QST (Rolke et al 2006a). Since there are no significant 
differences in QST parameters between the right and left sides of the body in healthy 
volunteers, we obtained QST reference values from one side of the body. In total, 418 
QST references from the upper and the lower extremity were obtained. 
2.2. Description of the patient cohort 
Patients with neuropathic pain lasting for more than three months were recruited from 
the outpatient Department of the Pain Management Unit of the University Medical 
Center Groningen, The Netherlands. Patients were diagnosed with neuropathic pain 
by the physicians of the Unit. Neuropathic pain diagnosis was made based on coherent 
patient history, medical history and physical examination which included neurological 
function tests. Each clinical diagnosis was additionally confirmed by an experienced 
pain specia list of the Pain Management Unit based on patient's files. In total , 108 
neuropathic pain patients (age range 22-75 years), of which 54 fema les (age 52.7 ± 12.8 
years) and 54 males (age 50.9 ± 13.0 years). Prior to the QST assessments ,  patients were 
asked to rate their ongoing pain level using a Numerical Rating Scale (NRS) of 'O' 
indicating "no pain", and ' 100' indicating "most intense pain imaginable". Patients did 
not discontinue their regular pain treatment if applicable. Patients underwent the QST 
assessment , at the area where the most profound pain was experienced (leg: n=59, arm: 
n=25, thorax: n=9, groin: n=4, back: n=3, cervix: n=3, abdomen: n=2, shoulder: n=2, 
flank: n=l). 
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2.3. Quantitative sensory testing (QST) 
The QST battery consisted of seven tests, measuring thirteen parameters and was applied 
according to the standardized protocol (Rolke et al 2006a). QST was performed by two 
research nurses, who underwent a comprehensive t raining at the DNFS in Germany. 
All tests were performed at the same research facility of PRA Int., Groningen, The 
Netherlands. The average room temperature was 23.1° C ± 1.7° C. 
Thermal QST tests were performed using the Pathway System (Medoc, Israel) and 
consisted of six parameters: threshold assessments for warm and cold detection ( W OT, 
CDT) and heat pain and cold pain (HPT, CPT). In addition, subjects were asked about 
paradoxical heat sensations ( PHS) during the thermal sensory limen ( TSL) p rocedure 
of alternating warm and cold stimuli. 
Mechanical QST tests consisted of seven different parameters. The mechanical detection 
threshold (MDT) was determined with modified von Frey filaments (Optihai r2-Set, 
Marstock Nervtest, Germany). The mechanical pain threshold (MPT) was measured 
with seven weighted pinprick devices (cylindrical, 0.2 mm in diameter flat contact 
area) with fixed stimulus intensities forces of 8, 16, 32, 64, 128, 256, and 512 mN. 
Mechanical pain sensitivity (MPS) was assessed using the same pinprick devices to 
obtain a stimulus-response relation. Dynamic mechanical allodynia ( OM A) was 
assessed as pa rt of the test above, using a set of three light tactile stimulators as 
dynamic innocuous stimuli: cotton wisp, cotton wool tip fixed to an elastic st rip and a 
standardized brush (SENSElab No.5, Somedic, Sweden). Vibration detection threshold 
(VDT) was performed with a Rydel-Seiffer graded tuning fork (64 Hz, 8/8 scale) that 
was placed over  a bony prominence. The wind up ratio ( W UR) test was assessed with a 
pinprick intensity of 256 mN. The pressure pain threshold ( PPT) was determined over 
muscle with a pressure gauge device (F DN200, Wagner Instruments, CT, USA). 
2.4. Neuropatliic pain grading 
For each of the neuropathic pain patients the diagnosis of neuropathic pain was 
confirmed using the grading system that categorizes neuropathic pain as "definite", 
"probable", "possible" or "unlikely" neuropathic pain ( Treede et al 2008). If a patient's 
pain complaints do not have a plausible neuroanatomical distribution and lack a history 
which suggests a relevant lesion or disease they are regarded as 'unlikely' neuropathic. 
If both requirements were fulfilled the working hypothesis 'possible' neuropathic pain 
was applied. If confirmatory tests such as positive or negative sensory signs confined to 
the innervations a rea of the relevant nerve structu re and a diagnostic test confirming the 
lesion or disease were both positive, patients were graded as 'definite' neuropathic pain. 
In case of only one positive confirmatory test, a patient's pain was graded as 'probable' 
neuropathic. If both confirmatory tests were inconclusive, a patient's pain was regarded 
as unconfirmed and patients were assigned 'possible' neuropathic pain. All patients in 
the present study were allocated to one of the four neuropathic pain grades. 
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2. 5. Data analysis and statistics 
2. 5.1. Z-transformation of QST data 
QST data of patient s with neuropathic pain were compared  with reference data from 
gender and age matched healthy subjects. Both, patients and healthy subjects were 
divided into two age g roups each (20-45 years ofage and 46-75 years ofage). QST values 
of ch ronic pain locations on the upper extremities were compared to QST reference 
values obtained from the dorsal hand of healthy controls (n=63 for females and n=29 
for males for age group 20-45 years; n=75 for females and n=42 for males for age g roup 
46-75 yea rs), whereas values from chronic pain locations on lower ext remities were 
compared to reference values obtained from the dorsal foot of healthy controls (n=63 
for  females and n=29 for males for age g roup 20-25 years; 11=75 for females and n=42 
for  males for age group 46-75 years). QST values from each patient were transformed to 
z- scores. A score above 1.96 or below -1.96 falls outside the 95% confidence interval of 
the mean reference value and was considered as  a sensory abnormal ity. Abnormalities 
were subsequently categorized as  either a sensory gain or a sensory loss. 
As it neveroccurs in healthy volunteers that dynamic innocuous stimuli become painful , 
the QST parameter "dynamic mechanical allodynia" ( OMA) could not be u sed  for z­
score analyses. In this case,  ratings greater than NRS 10 (scale 0-100) were regarded as 
clinically relevant and identified as abnormal. 
For the QST parameter " Wind-Up Ratio" ( W UR), eighteen patients rated the single 
pinprick stimulus as  "0" making ratio calculations (painfulness of one pinprick 
stimulation vs. painfulness of a t rain of ten pinprick stimulations) for Wind-Up 
impossible. For these patient s W UR was not used for subsequent analyses. Similar, 31 
healthy subject s rated the single pinprick stimulus as  "0" making ratio calculations for 
Wind-up impossible. 
2.5.2. Proportions of sensory signs/or tlie different neuropatliic pain grades 
To investigate the differences in the proportions of sensory loss, sensory gain or  mixture 
of sensory lo ss and gain for the different neuropathic pain g rades  we calculated the 
95% confidence intervals of the proportions using the 'Wilson Estimate' of proportion 
(Moore & McCabe 2003). 
2. 5.3. Correlation between tlie number of sensory abnormalities and 
neuropat/iic pain grades 
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For each grading numbers of sensory abnormalities were compared using ANOVA. 
The total numbers of sensory gain and sensory lo ss as  well a s  the overall numbers of 
sensory abnormalities across the thirteen QST parameters for  patients were correlated 
to the different neuropathic pain g rade s using Spearman correlations. 
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2. 5. 4. Correlation between background pain and neuropathic pain grades 
To identify a possible relationship between neuropathic pain grade and background  
pain of each patient, Pearson correlation was used . P-values <0.05 were regarded as 
significant for each statistical test performed .  
3. Results 
3.1. QST observations in healthy controls 
From the healthy volunteer cohort (n=209) investigated in this study, a total of 418 
locations were assessed and 5403 measurements were analysed by means of z-score 
profiling. The total of 1412 measurements for the most affected area were analysed by 
means of z-score profiling. 
3.1.1. Sensory loss and/or gain off unction 
Although the majority of the QST results obtained in healthy subjects confirmed normal 
sensory function for this cohort, incidental sensory abnormalities (4.3%) were observed 
for all QST parameters with the exception of OMA.  
Healthy subjects 
(n=418 test srtes) 
All patients (n=108) 
Defmrte NP (n=26) 
Probable NP (n=39) 
Possible NP (n=9) 
Un!Jkely NP (n=34) 
w no sensory abnormality 
0% 10% 20% 30% 
w only sensory gain Iii only sensory loss ■ sensory gain and loss 
--- - - - -
* * 
40% 50% 60% 70% 80% 
Fig. 3- 1 : Sensory findings (gain and/or loss of sensory function) in % for healthy controls 
(n=209 with 418 test sides), for patients (n=1 08) overall and ordered according to their l ikelihood 
100% 
to be neuropathic pain. "No sensory abnormal ities": none of the Quantitative Sensory Testing 
(QST) parameters were outside the 95% CI. "Only sensory gain": at least one QST parameter 
indicating thermal or mechanical hyperesthesia or hyperalgesia without the presence ofhypesthesia 
or hypoalgesia. "Only sensory loss": at least one QST parameter indicating thermal or mechanical 
hypesthesia or hypoalgesia without the presence ofhyperesthesia or hyperalgesia. "Sensory gain 
and loss": at least one positive sign combined with one negative sign. Wilson estimates of 
proportions between the groups of definite and probable neuropathic pain and the group of unl ikely 
neuropathic pain for only sensory loss and sensory gain and loss parameter (* p<0.05). 
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Out of the total of 418 different body areas that were tested across all healthy controls 
62% (259 locations) showed normal sensory function and 38% (159 locations) showed 
a sensory abnormality for at least one QST parameter. Sensory abnormalities were 
regarded as sensory gain in 21%, sensory loss in 13% and a mixture of sensory gain and 
sensory loss in 4% of the cases (Fig.3-1). 
3.2. Demographics of patients 
Demographic data of the patients are shown in Table 3-1. Apart from two patients, all 
patients reported ongoing spontaneous pain ranging from 3 to 100 (Mean 63.2 ± 22.8 
SD) on a 0-100 N RS just before the QST assessment took place. 
3.2.1. Clinical diagnose of neuropathic pain 
The aetiology of patient 's pain in our sample was diverse. The largest subgroup 
developed pain after a surgical inter vention (33) followed by patients who had a trauma 
(18). Other causes of pain were polyneuropathy (12), failed back surgery (10), pain after 
fracture (7), Herniated Nucleus Pulposus ( HNP) (6), spinal cord injury (4), peripheral 
nerve entrapment (4), central pain (3), amputation (3), Herpes Zoster infection (3), 
Radiotherapy (3), and pain after infection (2). The clinical diagnoses of patients included 
peripheral nerve injury (83), polyneuropathy (14), spinal cord injury (4), central pain (3), 
posther petic neuralgia (3) and complex regional pain syndrome (CRPS) (1) (see Table 
3-1). 
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Table 3-1: Patient characteristics 
ID Gender Age Pain Cause of Oinical Grading Grading Grading Grading Grading: Numbers of 
VAS (G-100) Pain Diagnose 1 2 3 4 Condusion abnormalities 
M 62 50 Polyneuropathy polyneuropathy yes yes yes positive definite NP 
F 43 60 Post stroke pain central pain yes yes yes positive definite NP 
M 52 75 Spinocerebellar ataxia central pain yes yes yes positive definite NP 
F S7 80 Diabetic polyneuropathy polyneuropathy yes yes yes positive definite NP 
55 90 Herniated nucleus pulposus peripheral nerve injury yes yes yes positive definite NP 
6 53 50 THU fracture spinal cord injury yes yes yes positive definite NP 4 
7 52 80 Sepsis and organ failures polyneuropathy yes yes yes positive definite NP 
71 60 Failed back surgery peripheral nerve injury yes yes yes positive definite NP 4 
51 75 Peripheral nerve entrapment peripheral nerve injury yes yes yes positive definite NP 4 
10 72 50 Failed back surgery peripheral nerve injury yes yes yes positive definite NP 
11 M 41 60 Failed back surgery peripheral nerve injury yes yes yes positive definite NP 
12 M 49 40 Accident with trauma peripheral nerve injury yes yes yes positive definite NP 2 
13 F 43 80 Postsurgical pain CRPSII yes yes yes positive definite NP 5 
14 48 60 Lesion of cervical myelum spinal cord injury yes yes yes positive definite NP 
15 M 53 70 Polyneuropathy polyneuropathy yes yes yes positive definite NP 
16 M 36 50 Accident with trauma peripheral nerve injury yes yes yes positive definite NP 
17 M 52 7S Myelopathy spinal cord injury yes yes yes positive definite NP 
18 M 46 0 Cruris fracture peripheral nerve injury yes yes yes positive definite NP 
19 M 66 75 Polyneuropathy polyneuropathy yes yes yes positive definite NP 
20 M 58 40 Herniated nucleus pulposus peripheral nerve injury yes yes yes positive definite NP 
21 F 65 70 Herniated nucleus pulposus peripheral nerve injury yes yes yes positive definite NP 
22 42 70 Peripheral nerve entrapment peripheral nerve injury yes yes yes positive definite NP 
23 M 38 90 Accident with trauma peripheral nerve injury yes yes yes positive definite NP 
24 F 43 100 Cervical myelopathy peripheral nerve injury yes yes yes positive definite NP 
25 75 80 Herniated nucleus pulposus peripheral nerve injury yes yes yes positive definite NP 
26 M 46 65 Failed back surgery peripheral nerve injury yes yes yes positive definite NP 
27 F 71 Herpes zoster postherpatic neuralgia yes yes yes none probable NP 6 
28 37 90 Postsurgical pain peripheral nerve injury yes yes yes none probable NP 4 
29 48 65 Accident with trauma peripheral nerve injury yes yes yes negative probable N P  
30 46 70 Accident with trauma peripheral nerve injury yes yes yes negative probable NP 
31 M 56 80 Postsurgical pain peripheral nerve injury yes yes yes none probable NP 
32 M 55 40 Accident with trauma peripheral nerve injury yes yes yes none probable N P  
33 F 53 80 Radiotherapy peripheral nerve injury yes yes yes none probable NP 
34 M 54 80 Postsurgical pain peripheral nerve injury yes yes yes none probable NP 
35 M 26 75 Accident with trauma peripheral nerve injury yes yes yes none probable N P  4 
36 56 Postsurgical pain peripheral nerve injury yes yes yes none probable NP 2 
37 59 60 Postsurgical pain peripheral nerve injury yes yes yes none probable NP 
38 25 70 Accident with trauma peripheral nerve injury yes yes yes none probable N P  
39 41 70 Postsurgical pain peripheral nerve injury yes yes yes negative probable NP 
40 67 85 Herniated nucleus pulposus peripheral nerve injury yes yes yes negative probable NP 
41 66 70 Postsurgical pain peripheral nerve injury yes yes no positive probable NP 
42 M 40 60 Amputation peripheral nerve injury yes yes yes negative probable NP 2 
43 M 23 70 Postsurgical pain peripheral nerve injury yes yes yes none probable NP 3 
44 62 80 Failed back surgery peripheral nerve injury yes yes yes none probable NP 
45 46 85 Postsurgical pain peripheral nerve injury yes yes yes negative probable NP 
46 54 65 Diabetic polyneuropathy polyneuropathy yes yes yes none probable NP 
47 46 40 Amputation peripheral nerve injury yes yes yes none probable NP 
48 M 63 80 Postsurgical pain peripheral nerve injury yes yes yes negative probable NP 
49 M 26 85 Accident with trauma peripheral nerve injury yes yes yes negative probable NP 
50 27 70 Femur fracture peripheral nerve injury yes yes yes negative probable NP 
51 M 62 70 Accident with trauma peripheral nerve injury yes yes yes negative probable NP 
52 M 58 80 Postsurgical pain peripheral nerve injury yes yes yes negative probable NP 
53 F 58 90 Postsurgical pain peripheral nerve injury yes yes yes none probable NP 
54 M 73 10 Herpes zoster postherpalic neuralgia yes yes yes none probable NP 
55 41  70 Metacarpa I fracture peripheral nerve injury yes yes yes none probable NP 
56 M 57 75 Tibia fracture peripheral nerve injury yes yes yes none probable NP 
57 M 44 35 Postsurgical pain peripheral nerve injury yes yes yes none probable NP 
58 M 57 40 Polyneuropathy polyneuropathy yes yes yes none probable NP 
59 M 73 70 Polyneuropathy polyneuropathy yes yes yes none probable NP 
60 M 24 so Postsurgical pain peripheral nerve injury yes yes yes none probable NP 
to be continued on page 56 
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continued from page 55 
Table 3-/: Patient characteristics 
ID  Gender Age Pain Cause of Clinical Grading Grading Grading Grading Grading: Numbers of 
VAS (0-100) Pain Diagnose 1 z 3 4 Conclusion abnormalities 
61 61 20 Diabetic polyneuropathy polyneuropathy yes yes yes none probable NP 
62 75 50 Failed back surgery peripheral nerve injury yes yes yes negative probable NP 
63 73 25 Herpes zoster postherpatic neuralgia yes yes yes none probable NP 3 
64 44 45 Postsurgical pain peripheral nerve injury yes yes yes none probable NP 4 
65 51 70 Postsurgical pain peripheral nerve injury yes yes yes none probable NP 
66 M 4/  so Postsurgical pain peripheral nerve injury yes yes no none possible NP 
67 M 43 90 Postsurgical pain peripheral nerve injury yes yes none possible NP 
68 M 70 10 Postsurgical pain peripheral nerve injury yes yes no none possible NP 
69 M 50 75 Spontaneous nb fracture peripheral nerve injury yes yes no none possible NP 
70 M 51 70 Postsurgical pain peripheral nerve injury yes yes no none possible NP 
71 M so 80 Postsurgical pain peripheral nerve injury yes yes no none possible NP 4 
72 M 59 60 Accident with trauma peripheral nerve injury yes yes no negative possible NP 2 
73 M 57 80 Postsurgical pain peripheral nerve injury yes yes no none possible NP 
74 52 100 Failed back surgery peripheral nerve injury yes yes no none possible NP 4 
75 M 43 60 Accident with trauma peripheral nerve injury yes no yes negative unlikely NP 6 
76 43 75 Meralg1a paresthetica peripheral nerve injury yes no yes none unlikely NP 0 
77 M 75 65 Postsurgical pain peripheral nerve injury no yes no none unlikely NP 
78 M 54 75 Postsurg1cal pain peripheral nerve injury no yes no none unlikely NP 
79 66 75 Accident with trauma peripheral nerve injury no yes 110 none unlikely NP 
80 F �9 75 lschem1c CVA central pain yes no no none unlikely NP 
81 M 37 60 Accident with trauma spinal cord injury no yes no negative unlikely NP 
82 65 so Amputation peripheral nerve injury no yes no negative unlikely N P  
83 M 59 55 Borrelia infection polyneuropathy no yes no none unlikely NP 
84 36 70 Cruris fracture peripheral nerve injury no no no none unlikely NP 4 
85 M 51  80 Failed back surgery peripheral nerve injury no no no negative unlikely NP 2 
86 M 46 65 Herniated nucleus pulposus peripheral nerve injury no no no negative unlikely NP 
87 41 55 Postsurgical pain peripheral nerve injury no no no none unlikely NP 
88 39 80 Postsurgical pain peripheral nerve injury no no no none unlikely NP 
89 M 32 40 Postsurgical pain peripheral nerve injury no no 110 negative unlikely NP 4 
90 M 49 85 Sternum fracture peripheral nerve injury no no no none unlikely NP 
91 M 42 80 Accident with trauma peripheral nerve injury no no no negative unlikely NP 
92 M 42 70 Failed back surgery peripheral nerve injury no no no none unlikely NP 
93 47 80 Accident with trauma peripheral nerve injury no no no none unlikely NP 
94 66 90 Postsurgical pain peripheral nerve injury no no no none unlikely NP 
95 M 71 20 Polyneuropathy polyneuropathy no no no none unlikely NP 
96 46 75 Accident with trauma peripheral nerve injury no no no none unlikely NP 2 
97 M 50 70 Radiotherapy peripheral nerve injury no no no none unlikely NP 4 
98 F 22 Postsurgical pain peripheral nerve injury 110 no no none unlikely NP 
99 49 so Accident with trauma peripheral nerve injury no no no negative unlikely NP 
100 50 10 Radiotherapy peripheral nerve injury no no no none unlikely NP 
101 75 90 Polyneuropathy polyneuropathy no no no positive unlikely NP 
102 61 80 Postsurgical pain peripheral nerve injury no no no negative unlikely NP 
103 M 73 10 Peripher.il nerve entrapment peripheral nerve injury no no no negative unlikely NP 
104 M 62 80 Polyneuropathy polyneuropathy no no no none unlikely NP 
105 M 29 60 Postsurgical pain peripheral nerve injury no no no none unlikely NP 
106 F 49 30 Failed back surgery peripheral nerve injury no no no negative unlikely NP 0 
107 M 60 80 Postsurgical pain peripheral nerve injury no no no negative unlikely NP 4 
108 M 57 50 Polyneuropathy polyneuropathy no no no negative unlikely NP 
Demographic patient overview; Quantitative Sensory Testi ng (QST) area indicates assessment 
location. Clin ical diagnose indicate the different neuropath ic pain entities. For al locating patients 
pain complaints as neuropathic pain a grading system was appl ied (Treede et al 2008). This grading 
determine with a greater level of certainty whether a pain condition is  neuropathic. To increase 
l ikelihood of neuropathy grading requires that pain in plausible neuroanatom ical distribution 
(Grading I ), that there is a h istory for a lesion or disease (Grading 2), sensory signs are in a 
neuroanatomical plausible distribution (Grading 3) and the presence of a positive confirmatory test 
(Grading 4) (none indicates that no test was performed). Number of sensory abnormalities reflects 
sensory gain sensory loss based on QST parameter exceeding CI 95% of z-scores. 
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3.2.2. Grading of neuropathic pain 
Patient's pain was graded into 'definite neuropathic' (n=26), 'probable neuropathic' 
(n=39), 'possible neuropathic' (n=9) and 'unlikely neuropathic' (n=34) according to the 
classification by Treede and colleagues (Treede et al 2008). Thus, of the 108 neuropathic 
pain patients investigated, 60% were graded as having 'definite' and 'probable' 
neuropathic pain. Out of this group 40% were accounted as 'definite' neuropathic. For 
patients graded as 'probable' neuropathic pain, 67% (n=26) a diagnostic test was not 
performed and 33% (n=13) had a negative outcome of the diagnostic test. Interestingly, 
in one patient with 'probable' neuropathic pain grading the diagnostic test was positive 
but the confirmatory test was negative (Table 3-1). 
All nine patients graded as 'possible' neuropathic pain did not have their sensory signs 
in a neuroanatomical confined territory. For this patient group more confirmatory and 
diagnostic work would be necessary to advance this group to 'probable' neuropathic 
pain. 31% of the clinically diagnosed neuropathic pain patients were graded as 'unlikely' 
neuropathic pain. This was due to the fact that there was a lack of history of patient's 
lesion or disease and their pain complaints were not in a plausible neuroanatomical 
distribution (Table 3-1 ). 
3.3. Type of sensory abnormalities in relation to neuropathic pain grading 
3.3.1. Sensory loss and/or gain off unction 
For the 108 patients investigated in this study, 1404 QST data measurements were 
obtained. In patients with neuropathic pain, sensory abnormalities were observed in all 
QST parameters. In our patient cohort, 94% had at least one QST abnormality. From 
these patients 51% had a mixture of sensory gain and loss, 26% had only sensory gain 
(hyperalgesia) and 16% had only sensory loss (hypesthesia) ( Fig. 3-1). 
The profiles of sensory signs in 'definite' and 'probable' neuropathic pain were not 
significantly different, but different from the 'unlikely' grade. This latter difference 
was due to an increase of a m  ixture of sensory gain and loss and a decrease in frequency 
of sensory loss only for the 'unlikely' grade compared to the 'definite' and 'probable' 
neuropathic pain grade (all p<0.05) (Fig. 3-1). 
These results indicate that profiles of sensory signs for 'definite' and 'probable' 
neuropathic pain differ from the profiles for the 'unlikely' grade. 
3.3.2. Individual QST parameters 
For the different grading groups ofneuropathic pain similar patterns of the distribution 
of sensory abnormalities were observed. Since the different neuropathic pain grades 
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showed comparable profile only the two most distant opponents i.e. 'definite' and 
'unlikely' neuropathic pain, are displayed for illustration in Figure 3-2. All neuropathic 
pain grades showed predominantly sensory gain changes for nociceptive QST parameters 
(CPT, HPT, PPT, MPS ,  W UR) reflecting hyperalgesia , whereas the non-nociceptive 






























Definite NP (n=26) 
_l_ 
Unlikely NP (n-34) 
CDT WOT TSL MDT VDT PHS DMA CPT HPT PPT MPT MPS WUR 
Fig 3-2: Quantitative Sensory Testing (QST) z-score abnormal ities in % for 'definite' neuropathic 
pain (top) and 'unl ikely' neuropathic pain (bottom) grading in 108 neuropathic pain patients. QST 
parameter are ordered as sensory parameters: Cold Detection Threshold (CDT), Warm Detection 
Threshold (WOT), Thermal Sensory Limen (TSL), Mechanical Detection Threshold (MDT), 
Vibration Disappearance Threshold (VDT), Paradoxical Heat Sensation (Pl-IS), Dynamic 
Mechanical Al lodynia (OMA) and nociceptive parameters: Cold Pain Threshold (CPT), Heat Pain 
Threshold (HPT), Pressure Pain Threshold (PPT), Mechanical Pain Threshold (MPT), Mechanical 
Pain Sensitiv ity (MPS) and Wind Up Ratio (WU R). Z-scores with positive sensory signs (gain 
of sensory function) plotted rightwards and negative sensory signs (loss of sensory function) 
plotted leftwards. Absence of OMA is normal and therefore no negative sign possible. 
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For the nociceptive parameters CPT and HPT, thermal pain thresholds were decreased 
indicating thermal hyperalgesia . An increased pain due to blunt pressure ( PPT) and 
an increased sensitivity to mechanical pain (MPS) were observed indicating only 
hyperalgesia for these parameters. For MPT a greater incidence for mechanical 
hypo- than hypersensitivity was detected. W UR was more frequently increased than 
decreased indicating a g reater incidence for hyper- than hyposensitivity. For almost 
every patient sensory loss was only observed for the non-nociceptive C DT indicating 
a thermal hypesthesia. In addition, thermal hypesthesias were observed in most of 
the patients for W OT and TSL. For MDT predominantly a sensory loss was observed 
indicating a mechanical hypesthesia . Except for two patients, it was not possible to 
detect hyperesthesia for VDT as the maximal value of 8/8 measured  by the tuning fork 
was within the normal range. P HS and DMA were found to be increased within all 
grading of neuropathic pain. 
These results show that sensory abnormalities for the individual QST parameters a re 
remarkably similar between the grades of neuropathic pain. These similarities were 
also reflected in the dist ribution for nociceptive and non-nociceptive QST parameters 
for the different neuropathic pain grades . 
3.4. Number of sensory abnormalities in relation to neuropathic pain grading 
The number of sensory abnormalities in neuropathic pain patients varied between 0 
and 9 for the thirteen QST parameters (see Table 3-1). In three out of the four grading 
categories, i.e. 'unlikely', 'definite' and 'probable' neuropathic pain, a small fraction 
of patients did not show any sensory abnormality upon undergoing the complete QST 
monitoring. 
When comparing the number of sensory abnormalities in the different categories of 
graded patients, the mean number of abnormalities for the group of patients g raded as 
'definite' neuropathic pain was 3.3 (SD ±  2.0). Similar numbers were also found for the 
group of patients with 'probable' and 'unlikely' neuropathic pain, 3.1 (SD ± 2.0) and 
3.4 (SD ± 2.1) respectively. Slightly higher was the number of abnormalities observed 
for the group of patients graded as 'possible' neuropathic pain (4.0, SD ± 1.8). This 
increase is not significant compared to patient groups graded as 'definite', 'probable' or 
'unlikely' neuropathic pain using ANOVA (Fig. 3-3). 
3.5. Background pain in relation to neuropathic pain grading 
Except for two patients, all patients reported  ongoing spontaneous pain (NRS mean 
63.2, SD ± 22.8) before the QST assessment took place (see Table 3-1 ). For patients 
graded as 'definite' neuropathic pain the mean NRS score for spontaneous pain 
were 65.2 (SD ± 20.3). Slightly higher pain levels were reported by patients graded 
as 'possible' neuropathic pain (68.3, SD ± 26.5). Patient's graded as 'probable' and 
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'unlikely' reported slightly lower pain levels of 60.9 (SD ± 23.8) and 62.8 (SD ± 23.0), 
















Definite NP (n=26) Probable NP (n=39) Possible NP (n=9} Unl ikely NP (n=34) 
Fig. 3 -3: N umbers of sensory abnormalities (sensory again and loss) for patients (n=1 08) graded as 
'definite', 'probable', 'possible' and 'unl ikely' neuropathic pain (N P); Mean values ± SEM. 
4. Discussion 
Investigating the somatosensory profiles of patients using QST showed that 
somatosensory abnormalities are a common feature in neuropathic pain. Applying 
the grading system for neuropathic pain revealed similar numbers of somatosensory 
abnormalities across the four different grading categories. Analysing the profile of 
sensory signs showed that overall the 'definite' and 'probable' neuropathic pain groups 
have an indistinguishable similar profile. The presence ofa mixture of sensory gain and 
loss as well as for sensory loss only differed significantly for these groups compared 
to the 'unlikely' grade. There was no significant correlation between background pain 
and the different neuropathic pain grades. 
The grading system allows a separation ofneuropathic and non-neuropathic pain based 
on profiles but not on the total amount of sensory abnormalities. Thus, the suggestion that 
patient selection based on grading of neuropathic pain may provide a more homogenous 
group of neuropathic pain patients for research and for clinical studies is only partly 
supported by the findings of this study. A more useful criterion for homogenous patient 
selection is the grading system since it allows a separation of neuropathic and non­
neuropathic pain based on somatosensory profiles. 
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4.1. Clinical diagnoses and grading of neuropathic pain 
All patients investigated in the present study were diagnosed with neuropathic pain 
based on clinical p resentation. Neuropathic pain is notoriously difficult to diagnose 
and due to the lack of a specific diagnostic tool a grading system to categorize pain 
as 'definite', 'probable', 'possible' and 'unlikely ' neuropathic was proposed ( Treede et 
al 2008). For 67% of the patients investigated, a di rect history of a relevant lesion or 
disease and plausibly distributed pain was confi rmed. These patients were subsequently 
graded at least as 'possible' neuropathic pain. In 26% of the patients such a plausible 
dist ribution of their pains was not identified, therefore these patients were graded as 
'unlikely '. For 29% of the patients no direct history of a relevant lesion or disease was 
identified. For these patients a greater degree of certainty than 'unlikely ' could not be 
reached. Overall, 32% of patients gained the neuropathic pain grade 'unlikely '. 
A small group of patients (8%) were graded as 'possible' neuropathic pain. Here 
confirmatory tests were either negative or  had not yet been performed, therefore this 
group of patients is regarded as having 'unconfirmed' neuropathic pain. This status is 
difficult to judge since clinical investigations determine this category. Any additional 
positive confirmatory test could change the status to neuropathic pain e .g. 'probable' 
and/or 'definite'. On the other hand, it has not been described how to proceed with the 
grading if future confirmatory tests were negative. For that reason the comparison of 
'definite' and 'probable' versus 'unlikely ' neuropathic pain grading is the most valuable 
for this paper. 
According to the classification criteria only definite and probable grades a re to be 
regarded as neuropathic pain ( Treede et al 2008). Therefore, 40% of patients investigated 
should be regarded as having non-neuropathic pain. Apparently, there is a mismatch in 
the outcome 'neuropathic pain' between the clinical observations / diagnosis and the 
grading system. Reason for such differences could lie in the fact that the grading system 
relies on a di rect relationship between cause of pain and its neuroanatomical plausible 
distribution to exclude 'unlikely ' neuropathic pain grade .  It could be argued that the 
grading system is "biased" towards precisely defined neuropathic pain entities. Once a 
distinct clinical entity is confirmed an increase in the certainty of neuropathic pain is 
almost an "epiphenomenon" since confirmatory evidence is often part of the assessment. 
Examples include neuropathic pain after a known surgical nerve lesion or  postherpetic 
neuralgia after shingles . F rom a clinical perspective such a direct relationship is 
sometimes difficult to establish. For example, a large group in the present study are 
postsurgical pain patients (n=33) which were diagnosed clinically with peripheral nerve 
injury. Out of this pool, seventeen patients were graded as 'definite' and 'probable', 
six patients as 'possible' and ten patients as 'unlikely ' neuropathic pain. For grading 
purposes, it has been suggested that the distribution of pain or hyperalgesia does not 
necessarily need to be identical to the innervations area of a peripheral nerve or root, 
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but it should be in a distribution that is typical for the underlying disorder (Treede et al 
2008). This is easy to recognise in well defined diseases such as postherpetic neuralgia 
where central sensitization might influence the distribution of sensory abnormalities. In 
contrast it is less clear in patients with postsurgical pain since it has been not established 
if damage to tissues other than nerves causes neuropathic pain after surgery (Macrae 
2008). 
Overall, 60% of the patients were graded as 'definite' and 'probable' neuropathic 
pain . Interestingly, different clinical neuropathic pain entities were found consistently 
within the grades of neuropathic pain. Only patients with postherpetic neuralgia were 
consistently graded as neuropathic pain. 
4.2. Somatosensory function in healthy controls 
Z-score transformation of QST data revealed one or more somatosensory abnormalities 
in 38% of the healthy control group. This number is in line with previous findings of 
41% abnormalities using the QST protocol (Maier et al 2010). 
For healthy volunteers , abnormalities were observed across all QST parameters with 
the exception of OMA. The detected sensory abnormalities reflected gain of function 
for the most part ,  some loss of function and in a minority a mixture of gain and loss of 
function (Fig 3-2). 
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4.3. Somatosensory Junction in neuropathic pain patients 
As expected, the large majority (93%) of neuropathic pain patients showed sensory 
abnormalities. Previously, a similar percentage (92%) of patients with at least one QST 
abnormality were reported (Maier et al 2010). Given the fact that for 7% of the patients , 
no abnormality could be detected,  QST and the cut-off of95% C I  of the mean reference 
values might be more stringent than clinical examination. 
In accordance with previous studies , sensory loss was predominantly found in non­
nociceptive parameters (Maier et al 2010; Scholz et al 2009), which could be associated 
with central or peripheral neuronal damage leading to ongoing pain via increased 
ectopic activity ( Liu et al 2000; Ochoa et al 2005; Serra et al 2009). Sensory gain 
was predominantly found in nociceptive parameters which could be associated with 
peripheral sensitization and/or altered central processing (Baron 2000; Baumgartner 
et al 2002; Sandkuhler 2009; Treede et al 1992; Wasner et al 2004). Overall , there was 
good agreement between our estimates of the expected range of sensory abnormalities 
in the general neuropathic pain patient population and those reported by Maier (Maier 
et al 2010). 
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4.3.1. Somatosensory function across the grading of neuropathic pain 
The pattern of sensory abnormalities for nociceptive and non-nociceptive parameters 
did not differ for the different neuropathic pain grades . A similar distribution of 
nociceptive and non-nociceptive parameters was previously reported in neuropathic 
pain patients (Maier et al 2010). 
Recently, Maier and colleagues reported in a QST study of 1236 neuropathic pain 
patients that profiles of sensory abnormalities differ in the neuropathic pain conditions 
(Maier et al 2010). Differences in profiles of sensory abnormalities were also observed 
in our study based on the grading system of neuropathic pain. The presence of sensory 
gain and loss and only sensory loss was similar for the grade of 'definite' and 'probable' 
but was significantly different to the grade 'unlikely' neuropathic pain. 
Our results indicate that the grading system allows a separation of neuropathic and non­
neuropathic pain based on profiles of sensory abnormalities. 
4.4. Background pain, number of sensory abnormalities and neuropathic 
pain grading 
QST revealed that the numbers of sensory abnormalities did not differ between the 
different neuropathic pain grades. This observation challenges the hypothesis that the 
number of sensory abnormalities is positively related to neuropathic pain grades using 
the grading system (Maier et al 2010). 
In a study with 618 neuropathic- and non-neuropathic pain patients, Dworkin 
and colleagues showed that pain intensity, unpleasantness, quality, and spatial 
characteristics differed significantly between these groups ( Dworkin et al 2007a). In 
the present study we have assessed the intensity of background pain prior to QST. There 
was no correlation between background pain intensity and numbers of somatosensory 
abnormalities in patients clinically diagnosed as neuropathic pain or for the different 
grades of neuropathy. 
The majority of patients investigated (93%) used their regular medication when the 
QST assessment took place. The medication could have influenced the sensory profiles 
detected. This is not ideal, but it reflects the most common situation in which QSTtesting 
is performed, clinically. Furthermore, all categories of the neuropathic pain grading 
include patients with medication. Apart from the ethical aspect of drug withdrawal 
leading to increased pain, many neuropathic pain medications have long elimination 
times and possible active metabolites, making drug withdrawal prior to testing both 
unwarranted and unpractical. 
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In conclusion, our results indicate that there is a mismatch between clinical 
neuropathic pain diagnoses and neuropathic pain grading outcome. Only 60% of 
patients with clinica11y diagnosed neuropathy were categorized as 'definite ' and 
'probable' neuropathic pain patients. Even if such a st ringent grading system may 
provide advantages in selecting homogenous groups for clinical research, numbers of 
somatosensory abnormalities within the diffe rent certainties of neuropathic pain are 
remarkably similar. The only significant finding to differentiate "true" neuropathic 
pain from "unlikely" neuropathic pain was the difference in somatosensory profiles , 
in particular with regard to the presence of the mixture of sensory gain and loss and 
only sensory loss. Neuropathic pain grades as we11 as numbers of sensory abnormalities 
were not cor related with patients reported background pain intensity. 
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Chapter 4 
A single QST parameter as a tool for 
mechanism-based investigation of 
neuropathic pain 
Konopka K.H., Harbers M., Houghton A., Kortekaas R., van Vliet A., 





Quant itative sensory testing (QST) allows the somatosensory profiling of patients with 
neuropathic pain. The ultimate goal of identify ing differences in the responsiveness 
to sensory stimuli is  the identification of differences in the mechanisms responsible 
for generating sensory abnormalities and their subsequent mechanism-based  therapy. 
Recently, it was shown that di stinct somatosensory patterns u sing a battery of QST 
tests are present in the different clinical entities of neuropathic pain. Until now, it has 
not been investigated whether the responsiveness to a single QST parameter would 
revea l different patient subgroups. Thus, we studied patients with neuropathic pain 
for their responsiveness to a single QST parameter "Mechanical Pain Sensitivity" 
(MPS). Abnormal MPS score reflects hypersensitivity for mechanical stimulation, 
which occurs in ~30% of the neuropathic pain patient population. The MPS test obtains 
stimulus-response function to seven pinprick devices exerting forces between 8-512mN 
to identify abnormalities for pinprick pain. In thi s study we found that patient s with 
MPS abnormalities showed two distinctive pattern s  of altered stimulus-response 
function to pinpricks. 40% of patient s reported a stimulus dependent pain response 
whereas 60% of patients did not show such stimulus dependent behaviour and rated 
all pinprick intensities equally painful. Both types of responses were found within 
different clinical entities of neuropathic pain. Hence, we show that even a single QST 
parameter can reveal additional, more detailed information of sensory abnormalities in 
neuropathic pain. Further evaluation might lead to the identification of differences in 
the mechanisms responsible for these distinct MPS abnormalities. 
1. Introduction 
The International Association for the Study of Pain ( IASP) defined neuropathic pain 
as a direct consequence of a lesion or dysfunction affecting the somatosensory system 
( Treede et al 2008). Neuropathic pain has traditionally been classified based on its 
underlying aetiology ( Hansson 2003); (Jensen et al 2001); ( Woolf & Mannion 1999). 
Until now, neuropathic pain classification according to the aetiology has been the basis 
for its pharmacological treatment, including tricyclic antidepressants, anticonvulsants 
and opioids (Attal et al 2010; Baron et al 2010; Dworkin et al 2007b; Wong et al 2007). 
However, improvement of pain complaints of more than 50% is achieved in less than 
one-third of neuropathic pain patients studied (Argoff et al 2006; Farrar et al 2001; 
McQuay et al 1996; Sindrup & Jensen 1999; Ziegler 2008). A way to provide more 
insight in the distinct underlying mechanisms for the different types of neuropathic 
pain patients is to investigate symptoms and sensory signs in greater detail. I deally, this 
could lead to a mechanistic understanding of the disease with subsequent improved 
treatment. 
With the development of standardized quantitative sensory testing (QST) protocols such 
as was provided by the DFNS group in Germany (Rolke et al 2006b), a methodology 
has emerged to characterise a full profile of somatosensation in each patient with 
neuropathic pain. Recently, Maier and colleagues reported in a study of l 236 neuropathic 
pain patients using this DFNS QST protocol that profiles of sensory abnormalities 
along 13 different QST parameters differ in the different neuropathic pain entities such 
as in postherpetic neuralgia, peripheral nerve injury, polyneuropathy and others ( Maier 
et al 2010). This study provides valuable information to generate understanding and 
concepts reflecting different sensory presentations of neuropathic pain. 
Because the convergence of multiple mechanisms into only one clinical symptom 
is probably the case for many of the different symptoms and signs in patients with 
neuropathic pain ( Woolf & Mannion 1999), an additional contribution to mechanistic 
studies of neuropathic pain could be the identification of somatosensory subgroups of 
patients based on a single QST parameter. Even for a single QST parameter, there might 
be differences in response within the group of patients that show abnormalities for this 
particular QST test. 
One of the parameters of the DFNS QST battery is Mechanical Pain Sensitivity 
( MPS). Abnormal MPS score reflects hypersensitivity for mechanical stimulation, 
a cumbersome phenomenon, which occurs in ~30% of the neuropathic pain patient 
population (Maier et al 2010). The MPS test obtains stimulus-response functions to 
identify sensory abnormalities for pinprick pain. 
In the present study we investigated whether a single QST parameter, i.e. M PS, 
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can be used to identify relevant subgroups of neuropathic pain patients , in this case 
characterised by a ltered mechanical pain sensitivity. According to the DFNS QST 
protocol , the geometric means of the numerical pa in ratings for the d ifferent pinprick 
stimuli are taken for further analysis ( Konopka et al a; Maier et al 2010; Raike et al 
2 006a; Raike et al 2006b). As an addition to the QST protocol , we performed stimulus 
response analyses , since these can be very informative and have been widely used to 
assess hypo- and hyperalgesic cutaneous reaction in clinical pain models (Fuchs et al 
2 001; Magerl et al 2001; Segerdahl 2006) and in patients (Stiasny- Kolster et al 2004). 
2. Method 
The study adhered to the declaration of Helsinki and all procedures have been 
approved by the medical ethical committee "Stichting Beoordeling Ethiek Bio-Medisch 
Onderzoek ,  P.O. Box 1004, 9400 BA Assen, The Netherlands", includ ing patients and 
healthy controls from the local region. All participants signed an informed consent 
form. 
2.1. Description of healthy controls 
In total, 185 age-matched healthy volunteers (age range 25-75 years), 119 females (age 
48.9 ± 10.5 years) and 66 males (age 51.9 ± 12 .4 years) underwent the QST assessments 
on their dorsal hand and dorsal foot. These body locations are indicated by Rolke et a J. ,  
2 006 as reference sides for QST (Rolke et al 2 006a). A previous study concluded that 
there were no significant differences in QST parameters between the right and left sides 
of the body in healthy volunteers (Rolke et al 2 006a), thus we obtained QST reference 
values from one side of the body. In total , 370 QST reference values were obtained. 
Healthy subjects were identified according to medical history. Subjects were specifically 
questioned about previous injuries or diseases. The healthy subjects did not use pain 
medication regularly and were free of medication at the time of the assessments . 
2. 2. Description of the patient cohort 
Patients were recruited from the outpatient Department of the Pain Management 
Unit of the University Medical Center Groningen, The Netherlands. All patients were 
diagnosed as suffering from neuropathic pain by the physicians of the pain management 
unit. Neuropathic pain diagnosis was made on grounds of coherent patient history, 
medical history, physical examination, including neurologic function tests. Each 
clinical diagnosis was additionally confirmed by an experienced pain specialist of the 
Pain Management Unit based on patient's files . In total, 127 neuropathic pain patients 
(65 females age 52 .4 ± 12.1 years and 62 males age 51.45 ± 12 .4 years) underwent the 
QST assessment , each at the area where the most profound pain was experienced (leg: 
n=70, arm: n=29, thorax: n=12 , back: n=4, abdomen: n=3, cervix : n=3, groin : n=2 ,  
n1 cdu raisms 
shoulder: n=2, flank: n=2). Patients did not discontinue their regular pain treatment, if 
applicable. 
2.3. Quantitative sensory testing (QST) 
The MPS testing procedures were applied according to the standardized protocol of 
Rolke et al., 2006 (Rolke et al 2006a). QST was performed by two research nur se s, who 
underwent a comprehensive training at the DNFS in Germany. All tests were performed 
at the same research facility of PRA International, Groningen, The Netherlands. The 
average room temperature was 22.9°C; SD ± 1.9°C. 
Mechanical pain sensitivity (MPS) was a ssessed u sing a set of seven pinprick devices 
(flat contact area of 0.2 mm in diameter) with fixed stimulus intensities that exerted 
forces of 8, 16, 32, 64, 128, 256, and 512 mN stimuli to obtain a stimulus-response 
function for pinprick-evoked pain, which activates Ac>-nocipectors (Ziegler et al 1999). 
A total of 35 pinprick stimuli were delivered. As part of the QST protocol, MPS test 
was intermixed with the assessment of Dynamic Mechanical Allodynia ( OMA). For 
OMA, three innocuous dynamic allodynia tools, cotton wisp, cotton bud and brush 
were applied (see Rolke et al., 2006) These stimuli were given in runs of 7 (five runs  
each), and each run consisted of a different p seudorandom sequence of seven pinprick 
stimuli and three dynamic allodynia stimuli. All stimuli were applied with a ~10 s 
inter-stimulus interval - well below the critical frequency for wind-up (temporal pain 
summation). 
After each stimulus application, subjects were a sked to give a pain rating for each 
stimulus on a '0-100' numerical rating scale (NRS) ( 'O' indicating "no pain", and '100' 
indicating "most intense pain imaginable"). 
2.4. Data analysis and statistics 
2.4.1. Z-transformation of QST data 
Pain rating to the seven different intensities of punctuates mechanical stimuli obtained 
from healthy subjects and patients are expressed as arithmetic mean and 95% con fidence 
intervals. Both, patients and healthy subjects were divided into two age groups each 
(25-44 years of age and 45-74 years of age). MPS data of patients with neuropathic pain 
were compared with reference data from gender and age matched healthy subjects. QST 
values of neuropathic pain locations at the upper extremities were compared to QST 
reference values obtained from the dorsal hand of healthy controls, whereas values 
from neuropathic pain locations at lower extremities were compared to reference values 
obtained from the dorsal foot of healthy controls. MPS values from each patient were 
transformed to z-scores a s  described by Rolke et al. , 2006 (Rolke et al 2006a). A score 
above 1.96 or below -1. 96 fa] ls outside the 95% confidence interval of the mean reference 
value and was considered a s  a sensory abnormality. Abnormalities were subsequently 
categorised as  either a sensory gain or a sensory loss. 
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2.4.2. Stimulus-response function for MPS in patients 
On ly patients who exceeded the 95% CI of the z- score transformation were eligible 
for further analyses of their stimulus-response functions for MPS. For patients with 
abnormal MPS z- score values, the stimulus-response function of the seven pinpricks, 
based on the mean of five stimuli each, were analysed. To identify differences in the 
pattern of the stimulus-response function the median of all seven pinprick forces was 
calculated. Each patient's median out of the seven pinprick ratings was calculated and 
compared to mean of five stimuli per pinprick intensity NRS rating. If the variance was 
greater than NRS ±10 of the med ian for two out of the seven pinprick intensities the 
presence of a stimulus-response function was recorded.  If patients did not exceed the 
variance of pain ratings of greater than NRS ±10 for six out of seven pinprick stimuli, 
the absence of a stimulus-response function for MPS was reported. 
2.4.3. Statistical analyses 
For healthy subjects, data were analysed u sing repeated measures ANOVA with 'age 
group' (25-44 years, 45-74 years) a s  within subject variables and 'gender (male/female) 
and location (arm/leg)' a s  between subject variables. 
Patients were divided into two groups according to their differences in the stimulus­
respon se function to pinpricks. For each individual, the slope of the stimulus-response 
function was analysed using a least square regression. The slopes between the two 
groups were tested  using t-test. 
All data are presented a s  group mean scores  with Standard Error of the mean (SE). For 
stati stical analysis SPSS 16.0 (SPSS Inc, Chicago ( I L), USA) was used.  
3. Results 
3.1. Stimulus-response function in healthy subjects 
In healthy volunteers, the painfulness of the different stimulus intensities for the 
pinprick forces was significantly different (F( l,181) = 12.93, p < 0.001), indicating that 
pain ratings increased with the increase in pinprick force (see Table 4-1). Taking gender, 
age and location a s  variables, only for location there was a significant effect found 
(F(6, 1086) = 3.57, p = 0 .02) showing that the pinprick forces were rated more painful 
at the leg compared to the arm. Therefore, for z- score transformation of MPS values in 
patients, MPS values for each of the two test locations were pooled with respect to the 
different gender and age groups of healthy controls. 
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Table 4-1: Overview of pain ratings for Mechanical Pain Sensitivity (MPS) in healthy subjects 
Pinprick Pain F < 45 hand F > 45 hand F < 45 foot F > 45 foot M < 45 hand M > 45 hand M < 4S foot 
Force n=40 test sites n=79 test sites n=40 test sites n=79 test sites n=19 test sites n=47 test sites n=19 test sites 
8mN Mean NRS 0.31 0.70 0 30 0.72 0 45 0.51 1 .02 
95% CI (-0.1 9}-(0.82) (-0.03}-(1.44) (0 07)-(0 53) (0 1 8)-(1 26} (-0 17)-(1 07) (-0.02)-(1.05) (-0.1 9}-(224) 
16mN Mean NRS 0.42 1 .01 1 .65 1 78 0 52 0 51 1 .39 
95% CI (-0 01)-(0.84) (0 28)-(1 75} (0 78}-(2 52} (0 90}-(2 66) (0 02)-(1 02} (-0.01)-(1.03) (0 16)-(2 61)  
32mN Mean NRS 0.78 1 .07 2.21 2. 1 8  0.96 1 .09 1 .69 
95% CI (0.16)-(1 .40) (0 39}-(1 ,74) (1.14)-(3.28) (1 1 4)-(323) (-0 08)-(2 01) (0.19}-(1 99) (0 01)-(3 36} 
64mN Mean NRS 2.57 2 44 3.61 3.54 1.40 2.43 2.95 
95% CI (1 .37)-(3 77) (1 49)-(3 39) (2.09}-(5.14) (2 29)-(4.78) (0 43)-(2.37) (0.86)-(4 00) (0.93)-(4 96) 
128mN Mean NRS 4.28 4 41 6.25 5.91 4 32 4 . 15  7 06 
95% CI (2.70}-(5 87) (2 88)-(5 93) (4.23)-(8.27) (4 26)-(7.57) (2 67)-(5 97) (2.33)-(5 96) (3 1 3)-(10 99) 
256mN Mean NRS 5.28 5 41 7.68 6.37 5.76 5.69 7.40 
95% CI (3.57)-(6 99) (3 80)-(7 01) (4 99)-(10 36) (4.66)-(8.07} (3.02)-(8 49} (2.96}-(8 42) (349)-(11 31) 
512mN Mean NRS 7.93 7 85 1 0.1 7 9 49 7.53 8.07 7 ,71 
95% CI (5.47)-(10 39) (5 81 )-(9 89) (6 91)-(13.44) (7.12)-(11 85) (4 74)-(10.31) (5.10)-(1 1 04) (4.34)-(1 1 09) 
Mean MPS Mean NRS 0.75 1 .08 1.26 1 .61 0.95 0.70 1 .46 
95% CI (0.37)-(1 .13) (0 38)·(1 . 78) (0.76)-(1 .76) (0.85)-(2.37) (0.24)-(1 .66) (0.23)-(1 1 7) (0 29)-(2.63) 
M > 45 foot 












(5 35)-(10 42) 
1 0.40 
(7 27)-(1 3.54) 
1.42 
(0 59)-(2.25) 
Mechanical Pain Sensitivity (MPS) stimulus-response functions for healthy controls (n=1 85). 
Controls are divided in two age groups (<45: age range 25-44 years and >45: age range 45-74 years). 
MPS assessment took place at dorsal hand (hand) and dorsal foot (foot). Stimulus-response 
functions were assessed by seven pinpricks exerting forces of 8mN, 16mN, 32mN, 64mN, 1 28mN, 
256mN and 5 1 2mN. Each subject rated the painfulness of each stimulus by Numerical Pain Rating 
(NRS) (0 no pain - 100 most imaginable pain). Geometric means of each value of five stimulations 
for each pinprick force were pooled and 95% CI are presented. 
3.2. Z-score transformation for MPS in patients 
From the 127 chronic pain patients investigated, 87 (68.5%) patients did not exceed the 
C I  95% of the z-score transformation and were regarded as normal responders to the 
test of MPS. 40 patients (31.5%) exceeded the C I  95% of the z-score transformation. 
None of the patient's z-score was greater than -1.96 indicating the presence of only 
sensory gain for MPS. 
3.3. Differences in pattern of stimulus-response function 
Investigating the stimulus response function of patients with MPS abnormalities revealed 
two distinctive groups of responders to pinprick stimulations. 40% of patients with 
abnormal z-score showed a stimulus-response function for MPS ( Fig. 4-1). Generally, in 
these patients an increase in the pinprick force resulted in an increase in pain response 
(NRS). In contrast, such stimulus dependent response in pain ratings was absent in 
60% of patients with MPS abnormalities (Fig. 4-2). Instead, patients consistently rated 
each individual pinprick force equally painful indicating an "all or none" phenomenon. 
Both patterns of pinprick responses in patients indicate a left-ward shift in painfulness 
compared to healthy controls and can be regarded as pinprick hyperalgesia. 
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Fig. 4- 1 :  Mechanical Pain Sensitiv ity (MPS) stimulus-response functions for  neuropathic pain 
patients (n=1 6). Patients with MPS z-score values outside of the 95% Cl showed a stimulus-response 
function to pinpricks. Stimulus-response functions were assessed by seven pinpricks exerting 
forces or 8mN, 16mN, 32mN, 64mN, 1 28mN, 256mN and 5 1 2mN. Each data point represents mean 
value for numerical rating scale (NRS (0-100)) for the painfulness of five stimulations for each 
pinprick force. 
The two groups of patients with differences in their stimulus-response function were 
further evaluated .  The linear fit analyses for each subject identified differences in 
the slope for the stimulus response function . For patients with a stimulus- response 
function the mean slope of the NRS for pain was 5.78 and for other patient group the 
NRS mean slope was 1.31 (Fig. 4-3). Significant differences between these slopes was 
confirmed by t-test (t=7.532, df = 39, p < 0.001). This result shows that two different 
types of responders to the pinprick stimulus-response function are present within the 
neuropathic pain patient population that show abnormal function in the MPS test .  
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Fig. 4-2: Mechanical Pain Sensitivity (MPS) stimulus-response functions for neuropathic pain 
patients (n=24). Patients with M PS z-score values outside of the 95% CI showed an absence 
of stimulus-response function to pinpricks. Stimulus-response functions were assessed by 
seven pinpricks exerting forces of 8mN, 16mN, 32mN, 64mN, 1 28mN, 256mN and 5 1 2mN. 
Each data point represents mean value for numerical rating scale (NRS (0-100)) for the painfulness 
of five stimulations for each pinprick force. 
3.4. Clinical diagnoses of patients with MPS abnormalities and different 
stimulus-response functions for pinpricks 
All patients with MPS abnormalities have been diagnosed with neuropathic pain. 
Patients with stimulus-response function for MPS included peripheral nerve injury 
(n=13), complex regional pain syndrome (CRPS)- 1 1  (n=l) and central pain (n=2). Similar 
clinical entities are reflected in the group of patients with a lack of a stimulus-response 
function for MPS. In this g roup, patients were diagnosed with peripheral nerve injury 
(n=14), polyneuropathy (n=6), central pain (n=3) and postherpatic neuralgia (n=l). 
Disease duration for  each of these two groups ranged between 1 year and 15 years. 
Similar clinical entities of neuropathic pain patients were for both g roups of MPS 
abnormalities indicating that the phenomenon of different responder to pinprick pain is 
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Fig. 4-3: Mechanical Pain Sensitivity (MPS) stimulus-response functions for healthy controls 
(n= 1 85) and neuropathic pain patients (n=40). Patients with M PS z-score values outside of the 95% 
Cl showed either a stimulus-response function to pinpricks (n= l 6) or absence of stimulus-response 
dependent function (n=24). Stimulus-response functions were assessed by seven pinpricks exerting 
forces of 8mN, 16mN, 32mN, 64mN, 1 28mN, 256mN and 5 1 2mN. Each data point represents mean 
value for numerical rating scale (NRS (0-1 00)) for the painful ness of five stimulations for each 
pinprick force. A significant di fference between the slopes of the two stimulus-response functions 
in patients is indicated by *** (p < 0.001). Error bars indicate SE. 
4. Discussion 
QST has been used to identify somatosensory abnormalities in patients with chronic 
pain including neuropathic pain. The ultimate goal of identifying differences in the 
responsiveness to sensory stimuli in neuropathic pain patients is the identification of 
differences in the mechanisms responsible for generating sensory abnormalities. A QST 
study recently published by Maier and colleagues, showed that sensory abnormalities 
along the thirteen different QST parameters can be categorised into specific patterns of 
abnormal sensory function and furthermore, that these patterns are represented in the 
different clinical entities of neuropathic pain (Maier et al 2010). 
An aspect which cannot be recognised in studies of patterns of sensory abnormalities 
along a series of QST parameters is the potential presence of differences in the 
responsiveness to a "single" QST parameter. In the present QST study we show that even 
a single QST parameter which is found to be abnormal in a subgroup ofneuropathic pain 
patients compared to healthy controls can reveal additional, more detailed information 
of sensory abnormalities. Investigating the stimulus-response function in patients with 
abnormal MPS values revealed two distinctive groups. 40% of patients with MPS 
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abnormalities showed as expected a stimulus dependent pain response whereas 60% 
of patients unexpectedly did not show such stimulus dependent behaviour and rated all 
pinprick intensities equally painful . Both distinctive groups of different responsiveness 
to MPS were found in different clinical entities of neuropathic pain. 
Thus, our results indicate that within the group of neuropathic pain patients who show 
abnormalities in the MPS test, distinct differences in the responsiveness to this single 
QST parameter exist. Further evaluation might lead to the identification of differences 
in the mechanisms responsible for these distinct MPS abnormalities . 
4.1. MPS abnormalities in neuropathic pain patients 
MPS was assessed as part of our QST screen of neuropathic pain patients . The 
occurrence of MPS abnormalities was 31.5% and reflected only sensory gain. Similar, 
the presence of sensory gain for MPS was reported to be 29.2% in a previous study 
in 1236 neuropathic pain patients (Maier et al 2010). On the other hand, we found a 
slightly lower prevalence (24.7%) of sensory gain for MPS in patients selected on the 
basis of their unilateral neuropathic pain ( Konopka et al a). 
4.2. Stimulus-response function for pinprick 
Static or punctuate hyperalgesia assessed by pinprick stimuli is mediated by nociceptive 
A8-fibre high-threshold mechanoreceptors ( LaMotte et al 1991; Magerl et al 2001; 
Ziegler et al 1999). In patients with spontaneous pain and hyperalgesia and in healthy 
subjects who were sensitised by an injection of capsaicin it was shown that by assessing 
the pinprick stimulus-response function also the degree of central sensitisation as 
measured by the shift in stimulus-response pain can be identified (Baumgartner et al 
2002). Such a left-ward shift in the stimulus-response function to pinpricks was also 
observed in patients with restless-leg syndrome (Stiasny-Kolster et al 2004). 
Central sensitisation refers to the increased synaptic efficacy established in neurons 
in the dorsal horn of the spinal cord following intense peripheral noxious stimuli such 
as tissue injury or nerve damage ( Koltzenburg et al 1994; Schaible 2007; Woolf 2010; 
Ziegler et al 1999). This enhanced synaptic transmission leads to a reduction in pain 
threshold and an amplif ication of pain responses. Pharmacological intervention studies 
showed that central sensitisation seen in patients with neuropathic pain and in healthy 
subjects using clinical pain models can be reduced (Belfrage et al 1995; Chizh et al 
2007; Gottrup et al 2004; Segerdah I 2006). 
QST studies investigating mechanical pain sensitivity regularly use only the geometric 
mean value out of the 35 stimuli to identify sensory abnormalities compared to the 
healthy controls (Magerl et al 2010; Maier et al 2010; Rolke et al 2006a; Rolke et al 
2006b). Investigating the QST parameter MPS in greater detail, e.g.  dose-response 
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function as we did in the present study gives more detailed insight in the abnormalities. 
Part of the patients (40%) with an abnormal MPS parameter showed a dose-response 
funct ion for the different pinprick intensities which reflects a left-ward shift when 
compared to dose-response function of healthy subjects. The other part , i.e. 60% of the 
patients , did not have a dose-response function to pinprick stimuli and rated each of the 
pinprick intensity equa11y painful. Such "a11 or none" response has been not reported 
previously. The observation of a loss of stimulus-response function in neuropathic pain 
patients with MPS abnormalities raises the question if the perception threshold and the 
maximum nociceptive activity are identical for this group of patients. In this context it 
is not clear if we have actua Jly "missed out" the starting point of a stimulus-response 
function by not lowering the pinprick force. A further reduction in pinprick intensities 
is technica11y difficult and the usefulness is questionable since a state of pinprick 
hyperalgesia is confirmed. Whether or not the observation of a minimal perceptive 
stimulus which already induces a maximum nociceptive activity represents itself as 
a disease continuum in neuropathic pain pat ients with pinprick hyperalgesia could be 
invest igated in longitudinal studies. 
We have observed different levels of"all or none" response in our study population . Some 
patients consistently rated their painfulness for pinpricks as relatively mild (NRS 10-
30) whereas others displayed high pain levels (NRS 60-95). Since QST is psychometric 
testing, it could be argued that the maximum pain response for each patient is also 
reflected in their rating. It could be presumed that in larger patient cohorts the "gap" 
between these responders can be filled. 
The majority of patients with MPS abnormalities (85%) used their regular medication 
when the QST assessment took place. The medication could have influenced the MPS 
abnormalities detected. This is not ideal, but it reflects the most common situation 
in wh ich QST testing is performed,  clinically. Furthermore, all MPS pattern include 
patients with and without medication. Apart from the ethical aspect of drug withdrawal 
leading to increased pain, many neuropathic pain medications have long elimination 
times and possible active metabolites, making drug withdrawal prior to testing both 
unwarranted and unpractical. 
The present QST study confirms that even a single QST parameter which is known to 
be abnormal compared to healthy reference values can reveal additional , more detailed 
information of sensory abnormalities. 
4 .. QST and ncn ropath ic lain mechanisms 
4.3. QST for mechanism-based studies in neuropathic pain patients 
QST data can be regarded as a rich source of valuable information of sensory 
abnormalities in chronic pain patients such as neuropathic pain. It is striking that 
sensory abnormalities for certain parameter such as Pressure Pain Threshold ( PPT) 
or Mechanical Pain Sensitivity (MPS) of the QST battery were by far more frequently 
observed than others. The prevalence of sensory gain for PPT and MPS overall i n  
neuropathic pain patients was reported to be 36.4% and 29.2%, respectively (Maier et 
al 2010). 
The identification of somatosensory phenotypes based on single QST parameter 
such as MPS can contribute to the viability of mechanism-based understanding of 
neuropathic pain. We showed that different "responders" to MPS exist i n  the population 
of neuropathic pain patients. From a mechanistic point of view the identification of 
phenotypical homogenous groups of different "responders" for even a single QST 
parameter e.g .  MPS might be useful. Future studies could evaluate if these different 
responders show differences in pharmacological responsiveness using different classes 
of pharmacological agents, e .g. sodium-channel blocker, antidepressants. I n  addition, 
if differences in  responders to other QST parameters could be identified,  with again 
distinct reactions to pharmacological interventions, a truly mechanistic picture of the 
somatosensory ofneuropathic pain patients could be emerging. As previous mentioned ,  
looking at QST profiles i nstead of a single parameter has shown its value to generate a 
mechanistic understanding of somatosensory abnormalities in neuropathic pain (Maier 
et al 2010). Our results add to that finding that one can even further subdivide the 
patients based on more detailed testing as we did using our specific MPS analysis 
approach. 
Our results indicate that multiple mechanisms e.g. different causes of neuropathic 
pain, can lead to the same sensory sign e.g .  MPS abnormalities. Moreover, that distinct 
different pattern of sensitisation to pinprick pain is common in different neuropathic 
pain aetiologies. This observation raises the question if these mechanistic differences in  
sensitisation could also explain the lack of efficacy of pharmacotherapy in neuropathic 
pain patients. 
In summary, a single QST parameter, i.e. MPS,  can be used to identify distinct subgroups 
of neuropathic pain patients , characterised by altered mechanical pain sensitivity. 
Part of the patients showed a clear stimulus-response to pinprick stimuli, while i n  the 
other part a stimulus-response to pinprick stimuli was completely absent. Both types 
of responses were found within different clinical entities of neuropathic pain. Further 
evaluation is necessary to identify potential differences in the mechanisms responsible 
for these distinct MPS abnormalities and their subsequent mechanism-based therapy. 
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Chapter 5 
Do patients with chronic patellar 
tendinopathy have an altered somatosensory 
profile? - A Quantitative Sensory Testing 
(QST) study 
C. P. van Wi )gen, K.H. Konopka, D. Keizer, J. Zwerver, R. Dekker 




The prevalence oftendinopathies in sports is high. The aetiology and pain mechanisms 
oftendinopathies are not completely understood.  Currently, little is known whether, or 
to which degree, somatosensory changes within the nervous system may contribute to 
the pain in tendinopathies. We conducted a patient controlled study in which we used the 
standardized QST protocol developed by the German Research Network on Neuropath ic 
Pain. This protocol consists of 7 different tests that measures 13 somatosensory 
parameters and can be seen as the gold standard to measure somatosensory function. 
Twelve athletes with clinically diagnosed chronic patellar tendinopathy ( PT) with a 
mean duration of symptoms of 30 months (range 6 - 120) and 20 control athletes were 
included in the study. In two of the thirteen QST parameters namely mechanical pain 
threshold (p <0.05) and vibration disappearance threshold (p  < 0.05) injured athletes 
were significantly more sensitive for the applied stimuli compared to controls. None 
of the athletes had signs of dynamic mechanical allodynia. Reduced mechanical pain 
thresholds or pinprick hyperalgesia reflects the involvement of central sensitisation upon 
the myelinated (A8-fibre) nociceptive input. From this explorative study we conclude 
that sensitisation may play a prominent role in patella tendinopathy patients. 
5 .. Q�"'1T urn patients ,vi h cndinopat 1y 
1. Introduction 
The prevalence of tend inopath ies in sports is h igh, well known sports related 
tend inopath ies a re ach illes tend inopathy in runners, patellar tend inopathy ( PT) 
in volleyball and basketball players and supraspinatus tend inopathy in swimmers 
(Chaudhry & Maffull i  2007; L ian et al 2005; Se in et al 2010). The aet iology and pa in 
mechan isms of tendinopath ies are not completely understood. A tend inopathy is 
considered to be an 'overuse injury' w ith a fail ing intratend inous heal ing response, 
w ith neoang iogenes is and/or neural reorgan izat ion (Rees et al 2009; Tan & Chan 2008). 
In the assessment of PT, pa in follow ing manual palpat ion of the tendon, together w ith 
a characterist ic h istory of increased pa in during and after (sport) act iv it ies a re the key 
elements for the d iagnosis, and can be confirmed w ith add it ional imaging techn iques 
such as Color Doppler Ult rasonography or Magnet ic Resonance Imag ing ( Warden et 
al 2007). However, not all symptomat ic athletes show tendon abnormal it ies on these 
imaging techn iques (Mall iaras & Cook 2006). 
An interesting quest ion is why pain occurs during or after exerc ise in both athletes w ith 
tendons show ing abnormal it ies on ult rasound scans but also w ithout abnormal it ies. A 
poss ible explanation for pa in in tendons may be the changes in somatosensory funct ion 
w ith in the nervous system itself i.e. sensit isat ion of the nervous system, rather than 
damage w ith in the tendon itself (Rees et al 2009; Webborn 2008). In the (sub-) acute 
phase, sens itisat ion is a phys iolog ic mechan ism that forces the pat ient to guard the 
affected body part, in order to enable t issue heal ing. However, somet imes sensit isat ion 
pers ists beyond the normal heal ing t ime; the pa in becomes chron ic. In PT pain typically 
occurs during or after exerc ise. This type of ongo ing pain represents a more or less 
irrevers ible state of hyperexc itability w ith in the central nervous system and could be 
considered as an important aspect in the development of neuropath ic pa in ( Woolf & 
Mann ion 1999). Sensit isat ion results in the clin ical symptoms allodynia - pa in due to 
a st imulus wh ich does not normally provoke pa in, e.g. pa in upon the l ight st rok ing of 
the sk in (dynamic allodyn ia) or pain during t ra in ing or exerc ise (mechan ical o r  k inet ic 
allodyn ia) and hyperalgesia - an increased response to a st imulus which is normally 
pa inful, e.g. intense pa in follow ing a moderate pa in st imulus (Merskey & Bogduk 2004; 
Svensson et al 2008; Treede et al 2008). 
Cl in ically, the ident ificat ion of s igns of pa in tenderness follow ing a manual palpat ion is 
one of the essent ial d iagnost ic criteria oftendinopathy. Recently, Webborn proposed in 
a rev iew that if no s igns of ongoing noc icept ion or pers istent inflammat ion can be found 
in tend inopath ies the presence of pers istent pa in can explained by neuropathic pain or 
by a psychogenic cause ( Webborn 2008). If noc icept ion and inflammat ion cannot be 
defined as plaus ible cause for a tend inopathy, it is reasonable to consider the possib il ity 
that an altered somatosensory profile i.e. sensit isation mechan isms may contr ibute 
or  even tr igger the occurrence of the pa in in PT. W ith Quant itat ive Sensory Testing 
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(QST) it is possible to assess perceptual functioning of somatosensory modalities 
that correspond with distribution areas to peripheral nerve fibres and CNS pathways 
( Hansson et al 2007; Ro Ike et al 2006a). QST examines large fibre function (A�), and 
nociceptive small fibre (A&, C) functions, all of which may be involved in peripheral 
and central pain syndromes (Raike et al 2006a). As QST is a form of psychophysical 
testing, alertness and cooperation of the patient is required for obtaining reliable test 
results . The cause of abnormal results may lie anywhere along the sensory pathway; 
from the peripheral receptor to the highest cortical regions in the brain (Chong & Cros 
2004; Hansson et al 2007; Shy et al 2003). 
Currently, little is known whether, or to which degree, somatosensory changes 
may contribute to the pain in tendinopathies and other sports injuries . Jensen et a l . 
investigated the presence of neuropathic pain mechanisms in 91 patients with chronic 
pate I lofemora] pain syndrome (Jensen et al 2008). They used somatosensory testing's 
and found significant hypesthesia on the affected side as opposed to the patients' own 
unaffected, contra]ateral side. In a c1inica] pilot study in patients with genera] chronic 
sports injuries we found signs of sensitisation in 27 % of the athletes and additional 13 
% showed signs ofhypoalgesia (van Wilgen & Keizer 2011). 
The primary goa] of this study is to investigate whether somatosensory changes 
represent a plausible exp lanation for pain in patient with chronic patellar tendinopathies 




In this patient controlled study we included only ma]e athletes with PT and male 
volleyball, basketball and soccer-players without PT in a control group . We included 
only male participants as gender differences have been reported for several QST 
parameters (Raike et al 2006a). Patients with PT, diagnosed by an experienced sports 
medicine physician or sports physical therapists were asked to participate in the study. 
The diagnostic criteria for PT inc1uded a characteristic history of knee pain in the 
proximal patellar tendon related to exercise and tenderness upon palpation of the 
patellar tendon. Patients with PT were included if their pain had been present for at 
least 6 months and if they scored lower than 80 points on the Victorian Institute of 
Sports Assessment - Patellar Questionnaire ( VISA-P). The V ISA-P is a validated, self­
administered questionnaire that is frequently used to evaluate the severity of symptoms, 
knee function and sports participation of athletes with PT (Visentini et al 1998). The 
psychometric properties of this questionnaire and the Dutch version in injured athletes 
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are adequate ( Visentini et al 1998; Zwerver et al 2009). 
Healthy control athletes were recruited from local sports clubs and through 
advertisements on websites. Inclusion criteria for participation of this study were a 
V ISA-P  score had to be above 90. All subjects were asked neither to take analgesics 
24h before participation in the study nor to take part in sport activities on the day 
of the study. Subjects with diseases or conditions associated with possible altered 
somatosensory function, such as a knee surgery, diabetes, fibromyalgia or neurological 
diseases were excluded. All participants signed an informed consent prior to their 
inclusion QST testing was approved by the Medical Ethical Commission (Stichting 
Beoordeling Ethiek Bio-Medisch Onderzoek Assen, The Netherlands). 
2.2. Quantitative Sensory Testing 
QST entails the measurement of the subjects' responses to standardized thermal and 
mechanical stimuli. QST is used to determine detection, disappearances and pain 
thresholds. The German Research Network on Neuropathic Pain - DFNS has developed 
a standardized QST protocol. This protocol consists of 7 different tests that measure 
13 parameters, including various types of mechanical and thermal detection and pain 
thresholds for the hand, foot and face (Rolke et al 2006a). QST was performed by 
two research nurses, who had undergone a comprehensive training at the DNFS in 
Germany. All tests were performed in the same research facility. Thermal QST tests 
were performed using the Medoc Pathway System (Medoc, Israel) and consisted of 
threshold assessments for warm and cold detection ( W OT, CDT) and heat pain and 
cold pain ( HPT, CPT). Thermal measurements were obtained with ramped stimuli (1 
�C/s) that were terminated when the subject pressed a button. Minimal and maximal 
temperatures were 0 and 50 °C. The baseline temperature was 32 °C. In addition, subjects 
were asked about paradoxical heat sensations ( PHS) during the thermal sensory limen 
(TSL) procedure of alternating warm and cold stimuli. 
Mechanical QST tests consisted of seven different parameters. The mechanical 
detection threshold (MDT) was determined with a standardized set of modified von 
Frey filaments (Optihair2-Set ,  Marstock Nervtest, Germany). The mechanical pain 
threshold (MPT) was measured using a set of seven pinprick devices with fixed stimulus 
intensities that exerted forces of 8, 16, 32, 64, 128, 256, and 512 mN. Mechanical pain 
sensitivity (MPS) was assessed using the same set of seven weighted pinprick stimuli 
to obtain a stimulus-response function for pinprick-evoked pain. Dynamic mechanical 
allodynia ( OMA) was assessed as part of the test above, using a set of three light tactile 
stimulators as dynamic innocuous stimuli: cotton wisp, cotton wool tip fixed to an 
elastic strip and a standardized brush (SENSElab No.5 Somedic, Sweden). Vibration 
disappearance threshold ( VDT) was performed with a Rydel-Seiffer graded tuning 
fork (64 Hz, 8/8 scale) that was placed on the patellar tendon; the vibration is graded 
from O to 8 (max). The wind up ratio ( W UR) test was assessed with a pinprick intensity 
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of 256 mN. The pressure pain threshold (PPT) was determined with a pressure gauge 
device (FDN200, Wagner Instruments, CT, USA). All PT patients and healthy controls 
were tested on the patellar tendon, directly distal to the apex of the patella. 
2.3. Questionnaires 
The DN-4 ( Douleur Neuropathique 4 questions) was assessed in the patients with PT 
in order to assess the presence of neuropathic pain symptoms. The 'classical' DN4-
questionnaire contains 10 items; the first 7 items, called the DN4-interview, are sensory 
descriptors that may be  applicable to the patient's pain, the remaining 3 items are related 
to physical examination signs; touch hypoestesia, pricking hypesthesia and brushing. 
Since we assessed a physical examination through the QST protocol, we only used the 
7-items DN-4-interview. For each positive item on the DN-4, one point is assigned. The 
cut-off score for neuropathic pain of the DN-4 interview was set at 4 or more positive 
items ( Bouhassira et al 2005). The results from the 'classical' DN4-questionnaire have 
been compared with the diagnoses of expert clinicians, DN-4 showed 83% sensitivity 
and 90% specificity and the DN4-interview demonstrated similar results ( Bouhassira 
et al 2005). 
Since psychological factors may interfere with pain perception, two psychological 
questionnaires were included. All participants filled out the Symptom Check List-90 
(SC L-90) and the Profile of Mood States (POMS). The SC L-90 is a multidimensional 
self-report inventory to assess various current psychological symptoms. The SCL-90 
yields 9 symptom domains of which the dimensions phobic anxiety, anxiety, depression, 
somatisation, insufficiency of thinking and acting, interpersonal sensitivity, hostility 
and quality of sleep were used in this study. Participants were asked to rate on a 5-
point scale from 1 (not at all) to 5 (extreme) how much each item had distressed or 
bothered them during the last 7 days, including the day of the examination. The SC L-
90 is a questionnaire that is used world-wide, the psychometric properties have been 
considered adequate (Arrindel & Ettema 2003). 
Furthermore the Dutch revised version of the ( POMS) was used (Robinson et al 2001). 
The POMS has been used extensively over the last years to understand the emotional 
responses to injuries ( Wiese-Bjornstal et al 1998) as well as to understand the relation 
between pre-competitive mood states and athletic performance ( LeUnes 2002). 
Originally the POMS consisted of 65 items; after factor analysis, support was found 
for a shortened version with 24 items and 6 dimensions ( Wicherts & Vorst 2004). For 
the Dutch POMS however, support was found for 5 domains and 32 items, namely: 
negative mood depression (8 items), anger (7 items), fatigue (6 items), positive mood 
vigour (5 items), and tension (6 items), with adequate reliability and validity ( Wicherts 
& Vorst 2004). 
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2.4. Statistical analyses 
The data of the thirteen measurements of QST in the injured athletes were compared 
to the healthy controls. Since some of the QST outcomes are ordinal data and most 
data were non-normally divided we used non-parametric tests ( Mann Whitney U). The 
descriptive data of the social demographic parameters are presented. Because of non­
normally divided data the SCL-90 and POMS dimensions were analyzed using non­
parametric (Mann W hitney U) test to compare injured versus control athletes. 
3. Results 
3.1. Participants 
The socio-demographic data are presented in Table 5-1; twelve PT  patients and 20 
control athletes were included in the study. All athletes were still training and or playing 
matches. The outcome on the VISA-P differed significantly between patients ( VISA-P 
62, SD 17.97) and controls ( VISA-P 99, SD 1.68). The median duration of symptoms 
for the PT group was 30 months (range 6 - 120). The outcome of QST assessment is 
presented in Table 5-2. 
Table 5-1: Socio demographic data of patients with a patella tendinopathy to healthy controls 
Patients Controls 
(n=l2) (n=12) 
Mean (SD) Mean (SD) 
Age (years) 23.3 (3.57) 24.7 (5.30) 
BMI  23.2 (3.61) 22.3 (1.92) 
Height 187.7 (7.40) 188.0 (7.64) 
VISA-P 62 (17.97)* 99 (1.68) 
p<0.05 compared to controls 
Sport Basketball (3) Basketbal I (7) 
Soccer (5) 
Vol leybal l (2) Soccer (7) 
Squash 
Rowing Volleyball (6) 
Education Highschool (9) Highschool (10) 
College/University (3) Col lege/University (10) 
3.2. QST 
In two of the thirteen QST parameters i.e. mechanical pain threshold and vibration 
disappearance threshold injured athletes were significantly more sensitive for the 
applied stimuli than for the control group (Table 5-2). None of the athletes showed signs 
of dynamic mechanical allodynia (DMA). The room temperature during QST testing 
was 23.7°C (SD 0.8). 
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Table 5-2: Results on the Mann Whitney test; comparing QST data of patients with a patella tendinopathy 
to healthy controls 
QST parameters Patients Controls z Mann Wh itney 
(n=12) (n=20) scores U Asymp sign. 
(2 tai led) 
Units Median (range) Median (range) p-value 
CPT QC 1 1 .27 0. 1 2  - 1 .25 0.2 1  
Cold Pain Threshold (0.00-26.47) (0.00-25.90) 
HPT QC 46.35 47. 1 3  -0.58 0.95 
(I) Hot Pain Threshold (40.70-49.80) (39.50-50.00) ,_ 
<U - PPT mN 78.00 74.00 -0.04 0.97 <U 
s Pain Pressure 29.33- 1 22.00) (37.33- 130.67) � Threshold ,_ � 
C. 
<U MPT mN 59.86 90.5 1  -2.03 0.04 




u MPS N RS** 0.60 0.25 - 1 .83 0.07 
0 Mechan ical Pain (0. 1 5-2. 1 4) (0.01- 1 .9 1 )  z 
Sensitiv ity 
WUR* 2 . 17  2. 1 3  -0.44 0.66 
Wind-up ratio ( 1 .03 - 19.00) ( 1 .04-1 0.00) 
CDT QC 4.40 3.20 - 1 .40 1 .6 1  
Cold Detection (2.03-8.40) (1 . 17- 14. 1 3) 
Threshold 
(I) ,_ 
QC <U WOT 4.73 3.73 -0.97 0.33 -
<U Warm Detection (2.47- 1 3 .53) (2.30- 13 .80) s Threshold � ,_ 
� TSL QC 1 0.95 8.90 -1 .09 0.28 C. 




MDT mN 2.77 2.46 -0.25 0.80 u 





0 VDT X/8 6.25 5.50 -2.53 0.01 z Vibration (4.83-7.83) (4. 17-6.83) 
Disappearance 
Threshold 
PHS X/3 0.00 0.00 - 1 .02 0.3 1  
Paradoxical Heat (0.00-3.00) (0.00-3.00) 
Sensation 
- * intensity of perception of series of I Hz vs. single, ** numeric rating scale 0-1 00 
n1 · .latncnts · it 1 c dino athy -=----------
3.3. Questionnaires 
None of the injured athletes scored 3 po ints or h igher on the DN-4. The SCL-90 and 
the POMS demonstrated no s ign ificant d ifferences between injured and non- injured 
athletes (Table 5-3). 
Table 5-3: Results on the Mann Whitney U test; SCL-90 and POMS. 
SCL 90 Patients Controls z Man n  Wh itney 
(n=12) (n=20) scores U Asymp sign. 
(2 ta i led) 
Median (range) Median (range) p-value 
Agoraphobia 7 (7-7) 7(7-9) -0.76 0.44 
Anxiety 1 0( 10- 1 2) 1 1  ( 10- 1 5) - 1 . 1 4  0.26 
Depression 17 ( 16-23) 18 ( 16-26) -0.86 0.39 
Somatisation 1 3 .5 ( 1 2-2 1 )  1 3 .5 ( 1 2-2 1 )  -0. 14  0.89 
I nsufficiency 1 1  (9-1 5) 1 0  (9-20) -0.90 0.37 
Sensitiv ity 1 9.5 ( 1 8-26) 20 ( 1 8-3 1 )  -0. 1 2  0.90 
Hosti l ity 6 (6-8) 6 (6-9) -0.53 0.60 
Sleep 3.5 (3- 1 1 )  3 .5 (3-7) -0.25 0.80 
Psychoneurotic 1 02 (90-1 1 8) 1 00.5 (91 - 143) -0.3 1  0.76 
POMS Patients Controls z Mann Wh itney 
(n=12) (n=20) scores U Asymp s ign. 
(2 ta i led) 
Median (range) Median (range) p-value 
Depression (0-4) 0.00 (0.00-0.50) 0.00 (0.00- 1 . 1 2) -0.24 0.8 1  
Anger (0-4) 0. 14  (0.00-1 .29) 0. 14(0.00-2.00) -0.08 0.94 
Fatigue (0-4) 0.33 (0.00-1 .00) 0.50 (0.00-1 .33) -0.91 0.37 
Positive mood 2.60 ( 1 .40-3.40) 2.60 ( 1 .40-3.80) -0.6 0.95 
vigour (0-4) 




Although most quantitative sensory tests demonstrated similar results for the patient 
group and the control group, we found several interesting differences. We found 
significant differences in mechanical pain threshold and vibration disappearance 
threshold in athletes with a chronic PT compared to healthy controls. In patients 
with PT no signs of mechanical dynamic allodynia could be found. No psychological 
differences between the two groups could be detected. 
Mechanisms of peripheral and central sensitisation have been described in several 
musculoskeletal disorders, such as chronic low back pain, fibromyalgia, whiplash, 
myofascial pain syndrome and other pain syndromes such as irritable bowel syndrome, 
chronic headache etc. (Nijs et al 2010; Winkelstein 2004; Yunus 2009). In sports injuries 
the role of sensitisation or lowered pain thresholds i.e. hyperalgesia has been described 
in patients with shoulder impingement ( Hidalgo-Lozano et al 2010) and patellofemoral 
pain syndrome (Jensen et al 2008). In our study injured athletes showed  considerable 
and significant aberrations of the mechanical pain threshold (MPT). This pinprick 
allodynia reflects the involvement of central sensitisation upon the peripheral input 
from the myelinated (AS-fibre) nociceptive input ( Davis & Pope 2002; Keizer et al 
2008). A reduced pain threshold of AS-fibre nociceptors is a plausible explanation why 
pain occurs during or shortly after sports activities. Such phenomenon is described to 
be very characteristic for (patellar) tendinopathy and is referred to in the classification 
of PT (Blazina et al 1973). A reduction of mechanical pain thresholds can be an 
explanation why sports activities that normally do not induce pain now become painful. 
Sensitisation accounts for the presence of a mechanical or kinetic allodynia in PT  and is 
therefore a logical explanation for the occurrence of pain in the patellar tendon during 
or after activities. 
The vibration disappearance threshold ( VDT) is a continuum measure, the differences 
found in VDT means that patients feel the vibration for a longer (median 6.25) period 
of time compared to the healthy subjects . This hyperesthesia could be regarded as a 
sign of an increased sensitivity in somatosensory function. The clinical relevance of 
this finding is difficult to interpret and has not been described previously. Further 
evidence that sensitisation might play a role in PT is that mechanical pain sensitivity 
was increased in patients . 
Webborn (2008) indicated that the pain in tendinopathy can possibly be seen as 
neuropathic pain ( Webborn 2008). According to the I ASP definition neuropathic pain 
is related to lesions within the nervous system (diagnoses such as diabetes, herpes 
zoster, poly-neuropathy or post surgery neuralgias) or as a dysfunction (low back pain, 
fibromyalgia) (Merskey & Bogduk 2004). Treede et al . (2008) suggested replacing 
the word 'dysfunction' with 'disease'. Neuropathic pain should be demonstrated with 
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a clinical examination for positive (hyperalgesia, allodynia) and/or negative signs 
(hypaesthesia) in addition to continuous ongoing pain. In our study tendinopathies could 
not be related to negative signs. Furthermore the DN-4 interview did not demonstrate 
that neuropathic pain descriptors could be used to describe the pain. With QST, no 
obvious signs of dynamic allodynia were found, although static pinprick allodynia 
could be demonstrated. Furthermore the patients did not have ongoing pain in rest but 
only evoked by pressure and physical (sport) activities. We can therefore conclude that 
-according to the Treede (2008)-criteria, PT in our patient population is not associated 
with neuropathic pain. 
However, sensitisation both centrally and peripherally may be a plausible explanation for 
the pain in (patella) tendinopathies. The question is why it arises and becomes chronic 
in some athletes but not in others. One explanation may be the extent of nociception 
that was originally present as a result of an extensive anatomical defect, severe and 
long-lasting nociception or (neurogenic) inflammation may cause more profound and 
irreversible sensitisation than relatively minor injury (Abate et al 2009; LaMotte et 
al 1991). However in general, athletes with chronic patella tendinopathy normally do 
not mention such an 'inciting event' causing severe nociception. Furthermore, genetic 
factors may be of importance, suggesting that some people tend to sensitises more 
vigorously than others (Magra & Maffulli 2008; Wang et al 2002; Zubieta et al 2003). 
Finally psychological and behavioral factors appear to play an important role in the 
maintenance of sensitisation (Gracely et al 2004). We did not find any differences in the 
psychological dimensions of the SCL-90 and P OMS. The outcome of the psychological 
dimensions in our population was average or below average compared to norm figures 
of healthy subjects (Arrindel & Ettema 2003). Behavioral factors may be an underlying 
factor explaining sensitisation in chronic tendinopathies such as not taking adequate 
measures at the onset of pain e.g. overuse, playing or training with pain and not 
taking rest adequately. Injured athletes appear to experience fewer consequences from 
musculoskeletal pain and tend to accept pain during sports (van Wilgen et al 2010). This 
behavior could be a risk factor leading to physiological changes in the central nervous 
system. In contrast, another psychological risk factor, fear of movement, which we did 
not specifically measure in this study may also be a risk factor (Silbernagel et al 2011). 
Future research on this topic is warranted. 
Explaining the pain in tendinopathy by sensitisation may give a better understanding of 
'successful' treatments currently used for tendinopathy. The positive effects of slightly 
painful eccentric programs or painful shock wave treatment without anesthesia on pain 
relief may not have local effect on the tendon but a more central effect i.e. explained by 
desensitisation of the CNS (Rompe et al 2009). 
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The outcome of the present study showed a large variability in different threshold values 
as measured with QST. Although QST is the golden standard to measure somatosensory 
aberrations its success depends on the participant's perceptions and concentration 
which may induce heterogeneity. Furthermore, earlier studies found hypesthesia on the 
affected side in some athletes this may be a subgroup and explain the large variability 
within the groups (Jensen et al 2008; van Wilgen & Keizer 2011). 
Further studies are needed to confirm whether the assessment for mechanical pain 
thresholds (myelinated A8-fibres) using standardized pinprick devices is adding to the 
clinical diagnosis of PT. A limitation of this study was that the diagnosis PT  was based 
only on clinical examination by a sport medicine physician or sport physical therapist ; 
no additional imaging techniques were used to investigate structural changes of the 
tendon which increases the likelihood of the diagnosis. On the other hand clinicians 
excluded patients with other knee pathology such as pate11a femoral pain syndrome, 
intra-articular pathology and ligament injuries. Furthermore, in the analyses of QST 
data mostly z-score transformations of data are used to identify sensory abnormalities 
wit h respect to controls (Rolke et al 2006a). Since z-score transformation and their 
interpretation is highly dependent on reference values we could not include such 
transformation due to the low numbers of participants , therefore in future studies larger 
groups should be included. Despite the fact that manual pressure pain thresholds for the 
clinical diagnose of PT has been used, the QST results for PPT showed no significant 
differences between the groups. The reason may be that we included patients with a 
long history of PT with pain evoked by sports activities. Furthermore a11 patients were 
measured on the same spot at the patella tendon and not on the most painful spot which 
is used in the clinical practice. In another study we measured athletes with PT and used 
an algometer (MicroF ET2 Biometrics BY). This algometer was shaped like a fingertip 
an applied on the most painful spot of the patella tendon. In this study lower PPT's 
and significant differences between patients and controls were found ( Kregel et al. , 
submitted). Looking back at this study, a similar approach would have probably yielded 
more pronounced differences between the patient group and the control group in our 
study. Another limitation was that we recruited healthy controls through advertisements 
on websites , this procedure might have led to selection bias. Furthermore, we did not 
take into account if athletes participated in sports activities the day before the study, 
th is may have interfered with the results of the study. 
4.1. Conclusion 
This is the first study investigating somatosensory aberrations in chronic patellar 
tendinopathy using a standardized QST protocol. Results of this explorative study should 
be interpreted as such as sensitisation might play an important role in the contribution 
of pain during and after sports activity in PT patients. 
)ati �nts , · i tl tcndlin )pathy ---------
4.2. Perspectives 
The pathophysiology of pain in chronic tendinopathy is largely unknown. We 
hypothesised that somatosensory changes may contribute to the pain in tendinopathies. 
From this explorative study we conclude that sensitisation may play a role in the 
explanation of pain during and after sports activity in patella tendinopathy patients. 
The diagnosis sensitisation may have consequences for the treatment and medical 
management of tendinopathies. Further studies however exploring the involvement of 
sensitisation in tendinopathy are warranted. 
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Chapter 6 




The assessment of sensory signs in chronic pain is of major importance in clinical 
practice, in part to help to identify neuropathic pain. Standardized Quantitative Sensory 
Testing (QST) such as by the DNFS (German Research Network on Neuropathic Pain) 
protocol is not only advantageous in the clinic for diagnosis , where sensory signs in 
patients can now be described quantitatively and qualitatively, but QST also facilitates 
new opportunities for research. QST can be categorized  as psychometric testing using 
both thermal and mechanical nociceptive as well as non-nociceptive stimuli. It allows 
the evaluation of different sub-modalities ofnerve fibres involved in the transduction of 
sensory information from the periphery to the spinal cord such as A�-fibres, A8-fibres 
and C-fibres. 
OriginaJly developed to explore the prospects of a mechanism-based classification 
of neuropathic pain, in this thesis additional potentials of QST are investigated. As a 
research tool it provides valuable information of differences in somatosensory function 
between healthy subjects and chronic pain patients. We have shown that in a substantial 
number of patients with unilateral neuropathic pain bilateral somatosensory changes 
are found. This challenges the application of sensory testing as a clinical evaluation tool 
when the contralateral side is used as reference side. Therefore, we suggest that only 
reference values obtained from healthy controls can be used for the correct interpretation 
of sensory signs in neuropathic pain patients . 
The results of our QST studies are also of re levance for the development of novel 
therapeutics in chronic pain, in terms of improved assay sensitivity. Examples are the 
selection of homogenous subpopulations based on specific QST parameters for the 
clinical evaluation of novel drugs, and the identification of distinct QST responders 
(e.g. Mechanical Pain Sensitivity) for mechanistic studies . 
Implications of QST for clinical neuropathic pain practice 
We demonstrated that by using QST values from healthy controls the interpretation of 
sensory function and its clinical manifestation for a patient with neuropathic pain may 
be different compared to the outcome based on bed side testing (chapter 2). In clinical 
practice, most often the contralateral ,  non-affected side of a patient is used as reference 
for the identification of sensory signs, such as hyperalgesia and allodynia, at the 
affected side. We have shown that in unilateral neuropathic pain bilateral somatosensory 
changes i .e . changes at the affected as well as the contralateral side occur frequently. 
Contralateral changes are in fact more rule than exception in unilateral neuropathic 
pain and could be attributed to plastic changes of the nervous system. These plastic 
changes might be "triggered" by pain since the presence of contralateral abnormalities 
was correlated with the ongoing pain intensity reported by patients . The observation of 
bilateral sensory abnormalities in unilateral neuropathic pain is very valuable clinically 
since it indicates that the contralateral side should  be used cautiously as a control side 
in sensory examinations such as bedside tests. We have shown that the interpretation of 
sensory function and its clinical manifestation can differ when either the contralateral 
side or the healthy volunteer data is used. To avoid potential misjudgement of the quality 
of sensory abnormalities we suggest that only QST reference values obtained from 
healthy controls are used. 
In this context it is unknown to which extent the potential misinterpretation of sensory 
signs in neuropath ic pain patients might have contributed to the lack of efficacy observed 
in the treatment of neuropathic pain. Based on our data , a direct comparison between 
the effects of treatment on sensory signs established with either bedside tests or the use 
of reference data would be useful. 
Assessing patients using the elaborate QST protocol can be very time-consuming and 
demanding for both patient and physician. For the assessments, patients need to be 
repositioned frequently to allow a correct application of stimuli. Thus, commonly a 
complete evaluation of the affected site ofneuropathic pain patients takes more than 45 
minutes. Such time- and labour intensive evaluation of somatosensory abnormalities 
limits QST for regular usage in the clinic. Indeed ,  the QST protocol needs to be 
simplified to become a regular screening tool in a clinical setting. In this context , it is 
of interest to identify the most sensitive QST parameters to determine somatosensory 
specifics for each neuropathic pain entity. 
To facilitate the diagnosis neuropathic pain, recently, a grading system was introduced 
by which the patient's pain can be categorized as definite ,  probable, possible or unlikely 
neuropathic pain (Treede et al 2008). This grading system is aimed to determine with a 
greater level of certainty whether a pain condition is neuropathic. 
We applied this grading system in a group of neuropathic pain patients and compared 
the results with those of the standardized QST protocol (chapter 3). Our findings show 
that the number of sensory abnormalities do not correspond with a greater level of 
certainty whether a pain condition is neuropathic, i.e., the number of somatosensory 
abnormalities were not different between the various grades of neuropathic pain. 
This result is striking since the presence of somatosensory abnormalities is a major 
aspect of neuropathic pain, which would predict that the more certain the diagnosis of 
neuropathic pain the greater the number of abnormalities. However, our results indicate 
that irrespective of the degree of neuropathic pain the somatosensory response e.g. 
numbers of abnormalities is similar for all diagnosis levels of certainty. In this context 
it would be interesting to investigate somatosensory abnormalities in non-neuropathic 
chronic pain diseases such as fibromyalgia and complex regional pain (CR PS- 1) in 
greater detail. Similarities in the frequency of QST abnormalities to those observed 
in neuropathic pain patients might point towards a "common final path" for the 
somatosensory system in chronic pain diseases. 
Whereas similarnumbersofsensory abnormalitiesfor the different grades ofneuropathic 
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pain were found in our study population, aspects of the pattern of sensory signs did 
differ between the highest and lowest level of certainty, i.e., between 'definite' and 
'probable' neuropathic pain and 'unlikely' neuropathic pain . Previously, it was reported 
that profiles of sensory signs differ even in the different clinical entities of neuropathic 
pain (Maier et al 2010). Unfortunately, the 1236 neuropathic pain patients included 
in that study were not analysed with respect to their neuropathic pain grades (Maier 
et al 2010). Studies in large populations of patients with different clinical entities of 
neuropathic pain and recognized neuropathic pain grades could evaluate the presence 
of specific profiles of somatosensory signs. The identification of differences in patterns 
of sensory abnormality in neuropathic pain patients could lead to a mechanistic 
understanding of somatosensory abnormalities in neuropathic pain. 
We reported earlier that in patients with unilateral neuropathic pain the presence 
of contralateral sensory changes was correlated with the intensity of ongoing pain 
(chapter 2). This was confirmed in a second study describing a larger and more diverse 
neuropathic patient sample (chapter 3). When we categorized the patients with respect 
to their certainty of neuropathic pain we found that this overa 11 effect was driven 
only by the group of patients graded as 'definite' neuropathic pain (r =0.642; p=0.01) 
(unpublished data). This finding indicates that the greater the pain intensity the more 
contralateral abnormalities occur, but only for the group of patients graded as 'definite' 
neuropathic pain . 
In the same study we have also identified a mismatch between clinical diagnosis of 
neuropathic pain and neuropathic pain grading. Only 60% of patients with clinica1ly 
diagnosed neuropathy were categorized as 'definite' and 'probable' neuropathic pain. 
This is an interesting finding in the context of the recently revised neuropathic pain 
definition. Accordingly, neuropathic pain is a direct consequence of a lesion or disease 
affecting the somatosensory system (Treede et al 2008). The grading system complements 
this definition and consequently 60% of our patients diagnosed as neuropathic pain 
were also graded as neuropathic pain. To what extent abnormal function of the 
somatosensory system oblige to this definition is in the context of our findings unclear. 
Similar, it remains unclear if the neuropathic pain grading could improve the efficacy 
in the treatment of neuropathic pain. However, this grading system certainly a1lows 
a precise selection of patients for clinical research and is therefore an interesting tool 
to translate findings into clinical practice and potentially increase patient's treatment 
satisfaction. 
Implications of QST for clinical neuropathic pain research 
The third study was designed to determine if QST would be a valid instrument to 
identify somatosensory homogenous groups of patients with neuropathic pain (chapter 
4). We found that a single QST parameter, i.e. mechanical pain sensitivity (MPS), can 
be used to identify distinct subgroups ofneuropathic pain patients. A part of the patients 
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studied showed a clear stimulus-response to pinprick stimuli, while in the other part a 
stimulus-response to pinprick stimuli was completely absent. Both types of responses 
were found within different clinical entities ofneuropathic pain indicating that multiple 
mechanisms e.g. different causes of neuropathic pain, can lead to the same sensory 
sign e.g. MPS abnormalities. Thus, distinct patterns of sensitisation to pinprick pain are 
common within different neuropathic pain aetiologies. 
The identification of somatosensory phenotypes based on a single QST parameter also 
contributes to the viability of mechanism-based understanding ofneuropathic pain. For 
this purpose, patients of both types of MPS responses could be further investigated 
using functional magnetic resonance imaging (fMRI). It has been already shown in 
human brain imaging studies that chronic pain induces structural changes and changes 
in brain function in different neural regions (Apkarian et al 2011; DaSilva et al 2008; 
Geha et al 2008; Gustin et al 2011; Schweinhardt & Bushnell 2010; Tracey 2007; 2008; 
Tracey & Bushnell 2009; Tracey et al 2002). FMRI studies of different MPS responders 
aimed to investigate potential group-specific changes in the brain might contribute 
to a mechanistic understanding of these differences. Pharmacological fMRI studies 
using different classes of drugs known to be efficacious in neuropathic pain should be 
utilised in this context. Knowledge of specifics in the efficacy of standard drugs for 
the different MPS responders could be translated into specific requirements for the 
pharmacokinetics and pharmacodynamics of novel compounds for clinical evaluation. 
Drug discovery is a very high-risk endeavour, and the time and costs of developing 
the compounds, as well as the methodologies to translate the research effort into 
medicines that better meet the needs of pain patients are challenging. QST phenotypic 
characterization e.g. MPS response pattern, as a tool for patient selection for enrolment 
into clinical trials could be used to decrease variance and increase the power to detect 
meaningful drug effects. In addition, knowledge gained in pharmacological intervention 
studies of this patient population could also help to determine a mechanism-based 
therapy for neuropathic pain. 
Implications of QST in non-neuropathic pain diseases 
Several studies indicate that sensory testing can be used to identify pathophysiological 
mechanisms and sensory differences across anatomical boundaries in chronic pain 
diseases. Kleinbohl and colleagues found that responses to phasic and tonic heat pain 
not only distinguished chronic pain from healthy controls but also discriminated among 
types of chronic pain (e.g. headache, back pain) with good sensitivity and specificity 
( Kleinbohl et al 1999). A study in complex regional pain (CR PS) grouped patients based 
on the spatial extent of sensory deficits showed that patients with more widespread 
sensory deficits also exhibit greater mechanical hypersensitivity in the affected limb 
(Rommel et al 200 1). Enhancement in the response to painful stimuli was also reported 
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in fibromyalgia (Staud et al 2004), temporomandibular disorders (Sar lani & Greenspan 
2003), pelvic pain syndromes (Granot et al 2002) and headache disorders (Bendtsen 
2000). Thus, somatosensory abnormalities are not limited to neuropathic pain (Cruccu 
et al 2004; Cruccu et al 2010). These studies indicate that QST can serve to objectify 
clinical findings and could be used to improve the selection of treatments . In this 
context, investigating if somatosensory changes contribute to the presence or absence 
of pain could be also valuable. 
In an exploratory QST study we showed that patients with chronic pate I Jar tend i no path ies 
had signs of sensitisation e.g .  decreased threshold for mechanical pain and an increased 
vibration disappearance threshold compared to age- and sports activity-matched 
pain-free controls (van Wilgen et al 2011; chapter 5). Thus, it was hypothesised that 
sensitisation might contribute to the presence of pain. 
Currently, little is known whether, or to what degree, somatosensory changes may 
contribute to the pain in tendinopathies. The pathophysiology of pain in chronic 
tendinopathy is largely unknown. The presence of sensitisation observed in this study 
is contradictive to the result of hypesthesia seen in a previous study (Jensen et al 2008). 
The differences in these studies could be explained by methodological differences. 
First, it is not known if sensory changes on the contralateral knee as seen in neuropathic 
pain also take place in tendinopathies. Therefore, in our study reference values were 
obtained from matched controls rather than using the contralateral side of patients. This 
could have contributed to a different outcome in the identification of sensory signs 
between these studies. Secondly, our study was aimed to identify pain contributing 
abnormalities in somatosensory function. Thus, we have used age- and sports activity­
matched pain-free controls for this investigation. Interestingly, overall impaired sensory 
function for these sport controls compared to healthy controls of our QST database were 
found (unpublished results). This result would suggest that high intense sports activity 
might influence sensory function, even if no pain was reported as by these controls. 
From this study we conclude that sensitisation may play a role in the explanation of pain 
during and after sports activity in patella tendinopathy patients. Larger QST studies 
could provide more evidence to what extent somatosensory changes contribute to the 
pain in tendinopathies. If such studies confirm the diagnosis sensitisation, treatment 
and medical management of tendinopathies could be adapted. 
Normative QST values in clinical research 
Normative QST data are generated by evaluating sensory function in healthy volunteers, 
a process that generally takes about 30 minutes in which one body area is assessed using 
the DFNS QST protocol. Ideally, normative data should be collected from different 
areas of the body since QST data are region specific (Rolke et al 2006a). Also age- and 
gender-specific differences were observed for some QST parameter (Rolke et al 2006a). 
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To harmonize the QST approach, standardized assessment areas such as dorsal hand 
and dorsal foot were introduced. For the purpose of our studies, we have followed these 
recommendations and used age- and gender-matched controls to compare QST data 
obtained from patients to identify somatosensory abnormalities. 
Z-score transformation of QST data revealed that one or more somatosensory 
abnormalities are also present in healthy controls, but its frequency was considerable 
lower than in patients. The likelihood in a healthy subject that all QST parameters (with 
exception of OMA, which is not present in healthy controls) are within the normal range 
can be calculated to be 54% (0.951 2). In accordance, our data showed normal sensory 
function for 53% of the healthy controls (n=209). In contrast, only 9% of patients showed 
normal sensory function (see chapter 3). Although overall, our healthy volunteer data 
is in line with data reported by others, there are differences encountered (Raike et al 
2006a; Raike et al 2006b). For instance, we found Paradoxical Heat Sensations ( P HS) 
>1 occurred in 1.4% at the test site "dorsal hand" and in 9.3% at the test site "dorsal 
foot". PHS > I in healthy subjects were not observed in previous studies (Ro Ike et al 
2006a; Raike et al 2006b). Such differences could be explained by the fact that z-score 
transformations depend on reference values. In this context minimum numbers needed 
as controls incorporating the complexity of the QST battery have not been established. 
There is a considerable variation in the literature concerning the choice of percentiles 
used to define reference values (Shy et al 2003). Ultimately, the choice of percentiles is 
dependent on a combination of clinical, disease-specific, personal and financial factors 
(O'Brien & Dyck 1995). Exchange of QST reference data between institutes would be 
favourable allowing QST access to the research and clinical community. A certified 
QST training is advantageous in this context to expand the QST database in co-operation 
with different institutes. We have participated in the QST training provided by the 
DFNS and differences in QST values in healthy subjects between institutions observed 
could be based on numbers of controls and/or regional differences in somatosensory 
function. The exchange of reference values could address potential regional differences 
and ultimately increases overall numbers ofreferences by reduced costs. Such a scenario 
might be also valuable to be implemented beyond European boundaries. 
Furthermore, detailed insight into normative QST values could be helpful in a more 
objective testing of drug efficacy in various neuropathic pain states. For regulatory 
purposes the FDA suggests pain as primary outcome measure for the evaluation of 
novel pain compounds. In clinical practice a pain decrease > 50% is desirable, however, 
this is only achieved in less than one-third of the cases (Argoff et al 2006; Farrar et 
al 2001; McQuay et al 1996; Sindrup & Jensen 1999; Ziegler 2008). For approval of a 
novel pain treatment a pain reduction of>30% on the visual analogue pain scale ( VAS) 
compared to placebo is required. Secondary outcome, which may play a major role in 
providing supportive evidence for approval of pain medication, can be, amongst others, 
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the positive influence on sensory signs such as hyperalgesia and allodynia. Improved 
knowledge of the subjective nature of pain and related sensory processes could help 
to optim ize the choice of study population and appropriate measurements for proof-of 
concept trails with putative pain therapies. 
Evidently, there is a need for normative QST values in the clinical evaluations of 
novel pain compound ,  which start with studies in healthy volunteers to provide safety, 
pharmacokinetic and possible pharmacodynamic information. In the latter case, 
subjects are exposed to acute pain tests such as pain threshold evaluation for thermal 
and mechanical stimuli. A subset of the standardized QST battery could be introduced 
to establish normative data of sensory function for clinical setting either with or 
without pharmacological intervention. The utility of different outcome measures in 
clinical trials could be investigated with the aim to maximise validity and reliability. 
Supportive to this idea is a study we performed investigating the test-retest variability 
of different acute pain tests for mechanical and thermal stimuli applied at the different 
body areas in healthy volunteers ( Konopka et al d). In this study each subject underwent 
different acute pain tests on th ree occasions over two weeks time. Results of this study 
revealed high between-subject variability for some parameters but not for all and a low 
within-subject variability for the different tests and test locations (in preparation for 
publication). 
High between-subject variability was also observed for some parameters of our QST 
database. For example, cold pain thresholds (CPT)  range between 2 .3 °C and 31.9 °C in 
healthy volunteers (n=209). It is obvious that with such a wide range of thresholds for 
cold pain a potential difference in efficacy ofnovel drugs compared to placebo might be 
difficult to establish. With an enriched study sample such as using only healthy subjects 
which have CPT's between 10 °C and 20 °C a potential drug effect would be more likely 
to be picked  up. An approach like this would increase the assay sensitivity by reducing 
variability. Furthermore, using a standardized approach to obtain reference values from 
healthy cont rols for pharmaceutical research allows the direct comparison of efficacy 
of compounds between studies. Such approach might allow a direct identification of 
superiority of novel compounds over other drugs at an early stage of development and 
potentially reduce costs. 
Another aspect of QST in clinical trials is bridging p reclinical and clinical studies 
to increase our understanding of the predictability of preclinical research. For both 
preclinical and clinical evaluation ofnovel treatments evoked stimuli are used to evaluate 
efficacy. Increase predictability of preclinical studies could lead to an increased success 
rate of a drug candidate to be t ransferred into clinic research. 
QST in clinical practice; general considerations 
Studies suggest that up to 5% of individuals undergoing surgery will develop severe 
persisting pain ( Keh let et al 2006; Poleshuck & Green 200 8). In a number of studies, 
pre-existing pain and high-intensity post-operative pain have been the p redictors of 
development of persisting pain after surgery (Bisgaard et al 2005; Katz et al 2005; 
Pluijms et al 2006; Poleshuck et al 2006). Another patient study showed that assessing the 
sensory characteristics of cancer-induced bone pain prior and after radiotherapy allows 
the identification in alterations in sensory responses. Alterations in specific sensory 
characteristics (e.g. abnormal warm sensation and pinprick pain) were associated with 
an increased likelihood of successful analgesia from palliative radiotherapy (Scott 
et al 2011). Individual differences in evoked pain sensitivity as potentially important 
prospective predictors of the course of clinical pain complaints have been suggested 
also in other studies. For example, pre -operative supra-threshold pain stimuli at 44 °C 
- 48 °C responses, but not heat pain thresholds predicted post-operative pain scores in 
women undergoing caesarean section (Granat et al 2003). 
Sensory testing can be also used as an outcome measure to document t reatment-related 
changes in somatosensory function. For example, opioid-induced hyperalgesia refers to 
a phenomenon whereby opioid administration results in a lowering of pain thresholds, 
clinically manifest as apparent opioid tolerance and worsening pain despite accelerating 
opioid doses. Recently, we proposed that sensory testing could help to identify opioid­
induced hyperalgesia and subsequently its differentiation from tolerance ( Konopka 
& van W ijhe 2010). This is clinically important, since tolerance can be overcome by 
dose escalation, whilst opioid-induced hyperalgesia may be aggravated by the same 
intervention. We have suggested that sensory testing should be performed prior to the 
anaesthesia at an a rea distant from the surgery site and subsequently up to a few hours 
post-operatively. Another aspect which has not been investigated is the situation that 
disease progression induces changes of sensory thresholds. If such changes occur and 
sensory abnormalities are present pre-operatively this in turn could blur post-operative 
sensory outcome measures and therefore might compromise the investigation of opioid­
induced hyperalgesia. In this context, reference values from healthy subjects could be 
used to establish normal sensory functioning in patients prior to anaesthesia. 
In conclusion, utilizing QST as a tool to assess sensory function does make sense, not 
only in patients with chronic pain but also in healthy subjects. In this thesis we have 
investigated the applicability of QST in clinical practice and for research purposes. In 
these studies we provide evidence that QST can lead to an improved characterisation 
of sensory signs in unilateral neuropathic pain, an improved understanding of 
sensory function in patients with different neuropathic pain grades and an improved 
understanding of somatosensory function as a pain-contributing factor in patients 
with patellar tendinopathies. QST also allows the identification ofhomogenous patient 
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populations which in subsequent studies could help to clarify the relationships between 
the aetiology and somatosensory function. The results of these studies contribute to 
a better understanding of sensory function in patients and indicate a great potential 
for QST as a research tool for clinical practice and drug development aiming for 
improvements in assay sensitivities. 
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Summary 
With the development of a standardized Quantitative Sensory Testing (QST) protocol 
by the German Research Network on Neuropathic Pain ( DFNS), a methodology is 
available to investigate somatosensory function in patients with neuropathic pain and 
healthy volunteers (for reference data). This QST battery tests different sub-modalities 
of nerve fibres involved in the transduction of sensory information. An increase in 
knowledge of somatosensory function is not only advantageous in the clinic, where 
sensory signs in patients can now be described quantitatively and qualitatively, but 
QST also facilitates new opportunities for research . Originally developed to explore 
the prospects of a mechanism-based classification of neuropathic pain , additional 
applications for QST are explored in this thesis . 
In chapter 2 and 3 the presence of sensory signs in patients with neuropathic pain 
was evaluated and scrutinized in the context of their clinical relevance. It has already 
been recognised that somatosensory abnormalities are commonly present in patients 
with neuropathic pain . In addition, we have shown that in unilateral neuropathic pain 
bilateral somatosensory changes occur frequently (i .e .  changes at the affected  as well as 
the contralateral side). The observation of bilateral sensory abnormalities in unilateral 
neuropathic pain is clinically very valuable since it indicates that one should be cautious 
in using the contralateral site as a "healthy" control area in sensory examinations such 
as bedside tests . Thus, in chapter 2 we resumed that to avoid potential misjudgement 
of the quality of sensory abnormalities we suggest that QST reference values obtained 
from healthy controls should be used. 
For diagnostic purposes a g rading system categorizing patient's neuropathic pain as 
definite, probable, possible or unlikely neuropathic pain was introduced .  This g rading 
system is aimed to determine with a greater level of certainty whether a pain condition 
is neuropathic. In our study described in chapter 3, only 59% of patients with clinically 
diagnosed neuropathy were categorized as 'definite ' and 'probable' neuropathic pain 
indicating a mismatch between clinical diagnosis of neuropathic pain and neuropathic 
pain grading. However, this result indicates that stringent grading of neuropathic pain 
may provide advantages in selecting homogenous g roups for clinical research . QST 
evaluation revealed that the numbers of somatosensory abnormalities were not different 
between the grading groups but profiles of sensory signs differed between definite and 
probable neuropathic pain g rades and unlikely neuropathic pain. 
It has been suggested that investigations of the differences in patterns of sensory 
abnormalities could lead to a mechanistic understanding of neuropathic pain . Such a 
mechanistic understanding could also be derived from investigations of a single QST 
parameter. In this context , for the QST parameter Mechanical Pain Sensitivity ( MPS) 
two distinctive patterns in the stimulus-response functions in neuropathic pain patients 
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were described in chapter 4. Since the MPS parameter can be used to identify distinct 
subgroups of neuropathic pain patients we indicate that these differences could be 
further investigated using functional magnetic resonance imaging (fMRI) combined 
with pharmacological inter ventions. Ultimately, knowledge from these studies could 
reveal mechanistic differences in neuropathic pain patients . 
Somatosensory abnormalities are not specific to neuropathic pain. In chapter 5, we 
investigated if QST is sensitive to identify somatosensory changes contributing to the 
experience of pain in patients with patellar tendinopathies. We showed that patients 
with chronic patellar tendinopathies had signs of sensitisat ion for some QST parameters 
compared to age and sports activity matched pain-free controls . Thus, we hypothesised 
that sensitisation might be contributing to the presence of pain. We have shown that 
investigating somatosensory function in these patients can serve to objectify clinical 
findings and could be used to improve the selection of treatments. 
Utilizing QST as a tool to assess sensory function is not limited to clinical practise and 
research. QST phenotypic characterisation can also be utilised for drug development 
to establish normative data and disease specific data. In turn, this could decrease 
variance and increase the power to detect meaningful drug effects in clinical studies. 
In conclusion, QST as a tool to assess sensory function does make sense in pain patients 
and healthy subjects . 
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Nederlandse samenvatting 
Met de ontwikkel ing van gestandaard iseerde Kwant itatieve Sensor ische Testen ( KST), 
ontwikkeld door het Du itse Onderzoeksnetwerk voor Neuropath ische P ijn ( DFNS), 
is er een methode beschikbaar gekomen om het somatosensor isch funct ioneren b ij 
pat ienten met neuropath ische pijn en gezonde vr ijw ill igers (voor referentiewaarden) te 
onderzoeken. Deze KST batter ij test versch illende submodal ite iten van de zenuwvezels 
d ie betrokken z ijn b ij de gele id ing van tastz intu iglijke informatie. Meer kennis over 
het somatosensor isch funct ioneren is van grote toegevoegde waarde in de kl iniek 
waar tastz intu igl ijke observat ies bij pat ienten nu zowel kwant itat ief als kwal itat ief 
kunnen worden beschreven. Tevens facil iteert KST ook n ieuwe mogel ijkheden voor 
onderzoek naar neuropath ische pijn. Hoewel KST oorspronkel ijk ontw ikkeld is om een 
mechanist ische class ificat ie van neuropath ische p ijn mogel ijk te maken, z ijn meerdere 
aanvullende toepassingen van KST onderzocht in <lit proefschr ift. 
In hoofdstuk 2 en 3 van <lit proefschr ift hebben we het somatosensor isch funct ioneren 
van pat ienten met neuropathische p ijn geevalueerd en kr it isch gekeken naar de kl in ische 
relevant ie van KST. Eerder onderzoek heeft aangetoond <lat somatosensor ische 
afw ijk ingen veelvuld ig aanwez ig z ijn bij  neuropath ische pijn pat ienten. W ij  hebben 
laten z ien <lat er bij  .!!__nilaterale neuropath ische pijn vaak ilaterale sensor ische 
verander ingen optreden (verander ingen d ie zowel aan de patholog ische kant a s e 
contralaterale "gezonde" kant van het l ichaam optreden). Het voorkomen van b ilaterale 
somatosensor ische verander ingen in un ilaterale neuropath ische p ijn is kl in isch 
zeer relevant aangez ien het du idel ijk maakt <lat men voorz icht ig moet z ijn met het 
gebru ik van de contralaterale l ichaamshelft als "gezond" controle gebied bij  kl in isch 
somatosensor isch onderzoek. Op basis h iervan stellen w ij in hoofdstuk 2 voor om KST 
referent iewaarden van een gezonde controle populat ie te gebru iken om een verkeerd 
oordeel over de kwal ite it van het somatosensor isch funct ioneren van pat ienten te 
voorkomen. 
Ter verbeter ing van de d iagnost iek is er een class ificat iesysteem ingevoerd <lat pat ienten 
met mogel ijke neuropathische pijn indeelt in de categor ieen absoluut, waarschijnl ijk, 
mogel ijk of onwaarschijnlijk neuropath isch. D it class ificat iesysteem is bedoeld om met 
een grotere mate van zekerhe id te kunnen bepalen of p ijnklachten neuropath isch van 
aard z ijn of n iet. In de stud ie beschreven in hoofdstuk 3 v inden w ij  <lat slechts 59% van 
de pat ienten met kl in isch ged iagnost iceerde neuropath ische pijn werden geclass ificeerd 
als absoluut of waarschijnl ijk neuropathisch. D it geeft aan <lat er een d iscrepantie is 
tussen de kl in ische d iagnose en het classif icat iesysteem voor neuropath ische pijn. Aan 
de andere kant zouden de strengere classif icat ier ichtl ijnen kunnen bijdragen aan het 
selecteren van meer homogene pat ientgroepen voor kl in isch onderzoek. De evaluat ie 
van de KST l iet z ien <lat het aantal somatos ische afw i"k ingen n iet versch ilde tussen 
de classif icatie categorieen. Het somatosensor ische profiel was ec ter we verschillend 
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voor de categor ie onwaarschijnlijk neuropathisch ten op z ichte van de categor ieen 
absoluut en ®arsch iinl ijk neuropath isch. 
Er is gesuggereerd dathetonderzoeknaar versch i I len in degatronen van somatosensor ische 
afw ijkingen kan resulteren in een beter inz icht in de fysiolog1sche mechanismen d ie 
aan neuropath ische p ijn ten grondslag l iggen. Een dergel ijke mechan ist ische v is ie 
van neuropath ische pijn kan ook gebaseerd worden op een enkele KST parameter. 
Binnen deze context hebben w ij  voor de KST parameter voor mechan ische pijn twee 
versch illende patronen in st imulus-responsefunct ie gevonden b ij neuropath ische p ijn 
pat ienten ( Hoofdstuk 4). Aangez ien de st imulus-responsefunct ie van mechan ische 
pijn gebruikt kan worden om verschillende subgroepen te ident ificeren b innen de 
groep neuropath ische p ijn pat ienten l ijkt het ons van belang deze subgroepen verder 
te onderzoeken met behulp van funct ionele Magnet ische Resonant ie Imaging fMRI) 
gecombineerd met farmacologische intervent ies. Mogel ijk zou met de verkregen kenn is 
versch illende fys iologische mechanismen kunnen worden ondersche iden b innen deze 
pat ienten groep. 
Afw ijkingen in het somatosensor isch funct ioneren z ijn n iet enkel van toepass ing op 
neuropath ische p ijn pat ienten. In hoofdstuk 5 is onderzocht of men met behulp van 
KST somatosensor ische verander ingen kon detecteren d ie mogelijk bijdroegen aan 
de p ijnklachten b ij pat ienten met patellatend inopath ie ( 'spr ingerskn ie'). W ij konden 
aantonen dat pat ienten met chron ische patellatend inopath ie sens it isat ie l ieten z ien op 
som m ige KST parameters vergeleken met gezonde controles gematched voor leeft ijd en 
hoeveelhe id sport ieve act iv iteiten. Op bas is van deze resultaten is onze hypothese dat 
sensit isat ie mechan ismen mogelijk bijdragen aan de p ijnklachten van deze pat ienten. 
We konden laten z ien dat het in kaart brengen van het somatosensor isch funct ioneren 
in deze pat ienten kan bijdragen aan een het object iveren van de klin ische bev ind ingen 
en mogel ijk de select ie van de ju iste behandel ing kan verbeteren. 
I 
Het gebru ik  van KST als instrument om het sensor isch funct ioneren in kaart te brengen 
hoeft z ich n iet te beperken tot de klin ische prakt ijk en onderzoek. Het karakter iseren 
van verschillende QST..9mfielen kan ook toegepast worden b innen de ontw ikkel ing 
van n ieuwe med icijnen en om normat ieve data voor gezonde controles en pat ienten 
populat ies te vergaren. D it zou kunnen le iden tot minder var iab ilite it en een toename 
in kracht om de effect iv iteit van med icat ie te kunnen detecteren in kl in ische stud ies. I 
Concluderend kan men stellen dat het gebru ik van KST als instrument om f 
somatosensor isch funct ioneren te meten nutt ig is b ij pat ienten met p ijnklachten en 
gezonde vr ijw ill igers . 
I 
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